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ABSTRACT 
 
Mammalian gonadogenesis is a complex 
orchestration of genes and signaling 
cascades, leading to differentiation of the 
gonadal primordium into either an ovary or a 
testis. The Y-chromosomal Sry drives testis 
differentiation, and ovarian development 
requires a means of disabling the testis 
pathway. Anti-Müllerian hormone (AMH) is 
a testicular product that induces regression of 
the Müllerian ducts in males. Postnatally, 
ovarian folliculogenesis is regulated by 
endocrine, paracrine, and autocrine 
mechanisms that pprepare the oocyte for 
fertilization. In addition to follicle-
stimulating hormone (FSH), AMH and 
oocyte-derived ligands of the transforming 
growth factor β (TGF-β) superfamily 
influence follicle growth, involving balanced 
proliferation and apoptosis of the granulosa 
cells. Intracellularly, the regulatory cascades 
employ a number of secondary messengers 
as well as transcription factors to drive cell-
specific gene expression.  
 
In Finland, the fourth most common 
malignancy among women is ovarian cancer, 
with sex cord-derived granulosa cell tumors 
(GCTs) accounting for 5% of all ovarian 
cancer. GCTs are steroidogenically active 
and may present with abdominal pain, 
menstrual cycle disorders, and secondary 
findings due to hyperestrogenism. Granulosa 
cell tumorigenesis is thought to arise from 
misregulation of granulosa cell proliferation. 
With the help of animal models, some 
molecular defects have been elucidated, but 
the exact mechanisms underlying human 
GCT pathogenesis are poorly known. 
 
The GATA transcription factors are 
suggested to play a role in gonadogenesis and 
folliculogenesis in mice. Each of the six 
GATA factors possess two zinc fingers and 
regulate cell-specific gene expression in 
various organs. Together with steroidogenic 
factor 1 (SF-1), GATA-4 and GATA-6 
activate several endocrine target genes, such 
as AMH, inhibin-α, and aromatase, the 
proper expression of which is essential for 
ovarian function. Furthermore, GATA-4 is 
known to be an intracellular effector in the 
FSH pathway. The specificity of gene 
regulation by GATA factors is achieved by 
cofactors acting in concert with them. 
Accordingly, SF-1, CREB-binding protein 
(CBP), as well as FOG(friend of GATA)-1 
and FOG-2 are able to modulate gene 
transactivation by a given GATA protein. 
 
This thesis aimed at clarifying the impact of 
GATA-4, GATA-6, and FOG-2 on the 
development and function of the mammalian 
ovary and on GCT pathogenesis by profiling 
mRNA and protein expression in the normal 
mouse and human ovary and in the GCTs. In 
the fetal mouse, GATA-4 and FOG-2 were 
readily expressed in the bipotential urogenital 
ridge and in tovarian somatic cells. Also in 
the fetal human ovary, both GATA-4 and 
FOG-2 were expressed in somatic cells, in 
which GATA-4 may have an anti-apoptotic 
function. Given the role of GATA target 
AMH in the fetal testis, transfection assays 
with the AMH promoter were performed, and 
the results indicated that FOG-2 participates 
in inhibiting AMH activation by GATA-4 in 
the fetal ovary.  
 
In the postnatal human ovary, GATA-4 and 
FOG-2 expression was initiated in the 
granulosa cells of primary follicles, along 
with activation of granulosa cell 
proliferation. At later follicle stages, 
expression of GATA-4, GATA-6, and FOG-
2 was intermediate or high in granulosa and 
theca cells. Based on the expression profiles 
for these factors, their function and 
regulation in the granulosa cells were studied 
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with the use of in vitro cell cultures. In 
cultured human granulosa-luteal cells, which 
resemble the luteal gland, GATA-6 was 
upregulated by gonadotropins, supporting the 
role of GATA-6 in the luteal glands, which 
also express FOG-2. Furthermore, the growth 
factor TGF-β was able to upregulate GATA-
4 in mouse granulosa cells. GATA-4 was 
found to be essential for the activation of 
inhibin-α by TGF-β.  
 
Finally, the impact of GATA-4, GATA-6, 
FOG-2, and AMH on GCT pathogenesis was 
analyzed by comparing their expression 
levels in tumor tissue with markers of clinical 
behavior in a series of 80 GCT patients. Most 
of the GCTs exhibited intermediate or high 
expression of GATA-4, GATA-6, and FOG-
2. However, AMH expression was more 
often downregulated, which was associated 
with an increase in tumor size, indicating that 
AMH may be a growth suppressor for GCT. 
Moreover, high and thus normal sustained 
GATA-4 expression was associated with 
more aggressive clinical behavior of GCTs, 
supporting a role for GATA-4 in granulosa 
cell proliferation. 
 
In conclusion, the expression profiling and 
functional analysis coupled with results of 
previous studies indicate that transcription 
factor GATA-4 is a key component in the 
granulosa cell function. GATA-6, on the 
other hand, is involved in regulating 
steroidogenic function in gonads as well as in 
adrenals, whereas FOG-2 has a putative 
impact on the fetal ovary with regard to AMH 
inhibition. Lastly, the results indicate yet 
another functional role for AMH in human 
cancer. Since transcription factors are nuclear 
mediators for several ovarian signaling 
pathways, proper knowledge of their function 
in regulating development as well as 
tumorigenesis will give us insight into how to 
control and modify these cascades. This 
information may lead to improved 
diagnostics and enable new treatment 
strategies to be developed. 
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ABBREVIATIONS 
 
AMH  Anti-Müllerian hormone (also known as MIS, Müllerian inhibiting substance) 
Bcl-2  B cell leukemia-2 
BMP15 Bone-morphogenic protein 15 (also known as GDF9B, see below) 
cAMP  Cyclic adenosine monophosphate 
CBP  CREB-binding protein 
C/EBP  CCAAT enhancer binding protein 
cDNA  Complementary deoxynucleic acid 
CRE  cAMP-responsive element 
CREB  cAMP-responsive element binding protein 
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E  Embryonal day 
ERK  Extracellular signal-regulated kinase 
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FSH  Follicle-stimulating hormone 
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GDF9  Growth and differentiating factor 9 
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MAPK  Mitogen-activated protein kinase 
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mRNA  Messenger RNA 
PKA  Protein kinase A 
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INTRODUCTION 
 
Gene regulation is a fundamental process 
enabling a fertilized egg to differentiate and 
grow into an individual mammal. Majority of 
the molecular mechanisms have been 
evolutionally conserved from invertebrates to 
vertebrates. All of the information required 
for development and functioning of an 
individual is located in the DNA. In 
eukaryotic cells, histone proteins pack the 
DNA into chromatins, which may be in an 
inactive or active state. The state of the 
chromatin depends on its condensation; when 
the chromatin is condensed 
(heterochromatin), gene transcription is in an 
inactive state. However, during early 
embryogenesis, all genes are potentially able 
to be transcribed to mRNA.  
 
Transcriptional control is paramount in gene 
regulation, which involves proteins known as 
transcription factors. In general, a given gene 
has promoter and enhancer element(s), the 
DNA sequences of which are bound by 
transcription factors to activate expression of 
the gene in a temporal and spatial manner. 
Transcription factors make up roughly 10% 
of the genes in the genome and can be 
combined in families. The zinc finger 
transcription factors possess at least one 
finger-like formation that mediates DNA 
binding. Interestingly, the nuclear receptors 
for steroid hormones, such as androgens, 
estrogens, and cortisol, are zinc finger 
transcription factors that are activated by the 
given hormone. 
 
Transcription factors play key roles in the 
temporal and spatial activation or silencing of 
genes during embryonic development and 
during adaptive responses in differentiated 
cells of a grown individual. The different 
transcription factors form transcriptional 
modules to drive cell-specific gene 
expression. While all the cells contain the 
same genetic information, the complex and 
specific network of transcription factors 
determines which genes remain active and 
which are silenced. The basic principle is that 
genes are not expressed unless transcription 
factors activate their promoters and 
enhancers; likewise, genes are silenced 
through inhibition of transcription factors’ 
function on the gene promoters, followed by 
inactivation of the promoters by methylation. 
Given that the methylated state of a given 
gene passes through cell division, a number 
of genes are permanently inactivated in a 
differentiated line of cells. 
 
An organ is comprised of a number of 
differentiated cell lines that provide its 
functional characteristics. The mammalian 
ovary possesses haploid germ cells, i.e. the 
oocytes, as well as cells of diploid somatic 
lineage, i.e. granulosa, theca, interstitial, and 
epithelial cells. Ovarian function has evolved 
as a specific interplay of these differentiated 
cells to prepare the oocytes for ovulation and 
fertilization, enabling them to develop into a 
new individual. Transcription factors play a 
key part in the interplay between endocrine, 
paracrine, and autocrine regulators in the 
ovary, as they orchestrate cell-specific gene 
expression and respond to extracellular 
signals to e.g. promote adequate proliferation 
and steroidogenesis. During recent years, the 
zinc finger transcription factor GATA-4 has 
evolved into one of the intracellular effectors 
in the gonadotropin pathway, the proper 
function of which is crucial for normal 
folliculogenesis. The roles of the six GATA 
transcription factors have been delineated in 
various organs, including the heart, lung, 
testis, and adrenals. Little is, however, known 
about their temporal and spatial expression 
and function in the mammalian ovary.  
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Impaired function of the transcriptional 
regulation machinery has direct implications 
for human disease. For example, abrogated 
GATA1 function causes problems in 
hematopoietic cells, haploinsufficiency of the 
GATA3 gene causes a hypoparathyroidism, 
deafness and renal dysplasia syndrome, and 
haploinsufficiency of the GATA4 gene is 
associated with congenital heart disease. 
Dysfunctional transcription machinery is also 
involved in tumorigenesis and cancer. Many 
cancer cells have lost significant parts of the 
differentiated phenotype of normal human 
cells and escaped cell cycle control. Cancer 
cells often have striking similarities with the 
undifferentiated embryonic cells. Considering 
that transcription factors may be targeted by 
pharmacological treatment modalities in 
cancer, improved understanding of their 
normal expression profiles and function will 
enable the development of novel and more 
efficient treatment strategies for cancer.  
 
This study was conducted to gain insight into 
the role of transcription factors GATA-4 and 
GATA-6 and their cofactor FOG-2 in the 
development and function of the mouse and 
human ovary and in human ovarian 
malignancies.
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REVIEW OF THE LITERATURE 
 
1 GATA family of transcription 
factors 
 
1.1 Structure and mode of action 
 
Transcription factors are proteins that bind to 
specific DNA sequences in the promoters 
and enhancers of genes and form specific 
transcriptional modules for a given gene to 
drive its expression. The GATA family 
consists of six zinc-finger transcription 
factors that commonly recognize and bind a 
consensus DNA sequence, 
(A/T)GATA(A/G), known as the GATA 
motif, in gene promoters and enhancers [1,2]. 
The six vertebrate GATA proteins (GATA-1 
to GATA-6) contain a homologous DNA-
binding domain, comprising of two 
distinctive zinc fingers, Cys-X-X-Cys-X17-18-
Cys-X-X-Cys (X represents any amino acid). 
GATA proteins also contain a basic domain 
with the nuclear localization sequence 
adjacent to the C-terminal finger and two 
separate transcriptional activation domains in 
the N-terminal part of the protein [1,3]. 
Further, the C-terminal zinc finger coupled 
with the basic domain is necessary and 
sufficient for DNA binding, and is able to 
bind a GATA-like sequence (AGATCTT, 
GATT, or GATC) in addition to the 
consensus GATA motif (Figure 1) [1,3,4]. 
The C-terminal zinc finger and the basic 
domains have been evolutionally highly 
conserved among species; in fact, the 
vertebrate GATA genes seem to have one or 
two common ancestors [5]. 
 
GATA transcription factors act in concert 
with a number of cofactors, coactivators, or 
corepressors to regulate gene expression in a 
given cell (Figure 1). For example, GATA-4 
interacts with Nkx2.5 and MEF2 proteins to 
drive cardiac gene expression [1,6], and with 
C/EBPβ and  steroidogenic factor 1 (SF-1) 
proteins to drive endocrine gene expression 
[7]. GATA-4 is also able to recruit and bind 
large transcriptional coactivator proteins, 
such as CBP (CREB-binding protein), which 
possess epigenetic tools to convert the 
chromatin to an active state [8,9]. In addition, 
GATA transcription factors themselves may 
act to open the chromatin to facilitate gene 
expression [10]. Finally, interactions with 
related GATA cofactors FOG-1 and FOG-2 
may fine-tune the gene activation. In initial 
studies on cardiac cells, FOG-2 was found to 
Figure 1. Simplified presentation of mode of action of GATA transcription factors on a gene 
promoter. The given GATA protein binds the GATA motif in the DNA predominantly by its 
C-terminal zinc finger. The cofactor FOG-1 or FOG-2 binds the N-terminal zinc finger, 
whereas CBP, a large coactivating transcription factor, binds the C-terminal finger. The 
transcriptional machinery that activates RNA polymerase to transcribe mRNA requires a 
number of additional transcription factors (TF).  
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enhance or suppress the promoter 
transactivation by GATA factors in vitro [11-
14]. Interestingly, the multi-zinc finger FOG 
proteins bind the N-terminal zinc finger of 
GATA proteins, in contrast to Nkx2.5, CBP, 
and p300, which bind the C-terminal zinc 
finger (Figure 1) [1]. 
 
1.2 Tissue-specific expression and 
function during development 
 
Based on similarities in amino acid sequence 
and expression pattern, the six vertebrate 
GATA factors have been divided into two 
subgroups. GATA-1, GATA-2, and GATA-3 
are predominantly expressed and functional 
in the hematopoietic cell lineage, whereas 
GATA-4, GATA-5, and GATA-6 belong to 
the endoderm-, and mesoderm-derived cell 
lineage found in the heart, blood vessels, 
lung, gut, adrenals, and gonads (Table 1). 
The expression patterns nicely correlate with 
the evolution of the six GATA factors, 
assuming that they had two ancestors or, 
alternatively, one that subsequently gave rise 
to the two GATA lineages by duplication of 
the DNA sequence [5]. With regard to 
embryonic functions, the phenotypes of 
various Gata-null mice show that GATA-6 is 
required for the earliest phases of endoderm 
differentiation, while GATA-4 is essential or 
lateral-ventral folding throughout the embryo 
(Table 1). However, as null mice for all Gata 
and Fog genes (except for Gata5) die in 
embryonic stage, these models do not allow 
analysis of the impact of these genes on later 
developmental stages and adult animals. 
Nevertheless, studies on expression patterns 
followed by functional analysis have 
delineated a great number of processes 
involving these transcription factors.  
 
GATA-4 and GATA-6 play distinctive roles 
in the development and function of the heart 
and adrenals. Fetal and postnatal cardiac cells 
express GATA-4 and GATA-6 [6], 
suggesting functions for both of these factors 
in this cell lineage. Indeed, a number of 
cardiac-specific genes possess GATA motifs 
in their promoters and are activated in 
concert by GATA-4 and GATA-6 [6,26]. 
With an extracellular stress stimulus, such as 
mechanical stretching of the ventricular 
walls, GATA-4 activity is enhanced through 
 
Gene/Protein Examples of expression Mouse -/- phenotype (reference) 
GATA-1 Hematopoietic cells, testis Lethal by E11 due to failure in 
hematopoiesis [15] 
GATA-2 Hematopoietic cells, embryonic brain, 
endothelial cells, fetal germ cells in ovary 
Lethal by E11 due to failure in 
hematopoiesis [16] 
GATA-3 T lymphocytes, placenta, kidney, adrenal 
medulla, central nervous system (CNS) 
Lethal by E12 due to failure in 
hematopoiesis and CNS [17,18] 
GATA-4 Gonads, fetal adrenal, heart, pancreas, 
intestine, primitive endoderm 
Lethal by E10 due to failure in 
ventral morphogenesis [19,20] 
GATA-5 Heart, lung, spleen, intestine, primitive 
endoderm 
Malformations in vagina, urethra, 
and clitoris in females [21] 
GATA-6 Gonads, adrenal, heart, lung, liver, 
pancreas, intestine, primitive endoderm 
Lethal by E7 due to block in 
endoderm differentiation [22] 
FOG-1 Hematopoietic cells, testis, liver Lethal by E12 due to failure in 
hematopoiesis (like GATA-1) [23] 
FOG-2 Gonads, heart, central nervous system  Lethal by E15 due to failure in 
heart development [24,25] 
     Table 1. Expression profiles and phenotypes of mice null for Gata or Fog genes. 
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activation of the mitogen-activated protein 
kinase (MAPK) pathway [27-29]. The 
activated GATA-4 may thus promote the 
development of cardiac hypertrophy, a 
disease characterized by increased size of 
cardiac cells and compromised cardiac 
function [27-29]. The GATA cofactor FOG-2 
is also required for cardiac development; 
Fog2-null mice die of congestive heart 
failure in utero, with atresia of the tricuspid 
valve, among other malformations [24,25]. 
Moreover, human mutations in the GATA4 
gene have been associated with cardiac 
malformations, including atrial and 
ventricular septal defects (ASD and VSD, 
respectively) [30]. 
 
In the adrenals, GATA-4 and GATA-6 are 
expressed in specific patterns during 
development. Fetal adrenocortical cells in 
mice and humans express GATA-4 and 
GATA-6, whereas postnatally only GATA-6 
is expressed [31]. These findings suggest that 
GATA-4 might support the proliferation of 
less differentiated cells in fetal life, while 
GATA-6 has roles in differentiation and high 
steroidogenic activity in adult adrenals. 
Consistent with this speculation, GATA-4 is 
upregulated in adrenal tumors in mice 
[32,33]. In addition to the adrenals and the 
heart, murine gonads express GATA-4 and 
GATA-6 [34-36].  The putative roles of these 
factors in the gonads, especially in the ovary, 
will be presented and discussed here. 
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2 Embryonic development of the 
female reproductive tract 
 
2.1 Bipotential gonad and sex ducts  
 
The capability of the gonadal primordium to 
differentiate into two gonads is a unique 
situation in embryology [37]. Prior to 
differentiation, a common precursor, the 
urogenital ridge, appears in the intermediary 
mesoderm of the embryo, later giving rise to 
the gonads and adrenals [37,38]. The 
mammalian germ cells migrate from the 
extraembryonic mesoderm of the yolk sac to 
the urogenital ridge. Germ cell arrival 
subsequently induces proliferation of the 
somatic epithelial cells of the urogenital 
ridge and development of the bipotential 
gonadal primordium (Figure 2) [37,38]. 
Besides the undifferentiated gonad, an XY or 
XX embryo also possesses the anlagen for 
the rest of the male and female reproductive 
tract, the Wolfian and Müllerian ducts, 
respectively (Figure 2).  These sex ducts 
form within the mesonephros in a process 
requiring proper function of a number of 
genes, such as Wnt4 and Wnt7a [39,40]. The 
development of the Wolfian duct derivates, 
i.e. the epididymides, vas deferens, and 
seminal vesicles, in males and the Müllerian 
duct derivates, i.e. the fallopian tubes, uterus, 
and upper vagina, in females is dependent on 
anti-Müllerian hormone and testosterone 
produced by the fetal testis and estrogen 
produced by the ovary. 
 
2.2 Regulation of sexual differentiation 
 
The differentiation of the mammalian ovary 
is commonly explained as a passive event 
occurring in the absence of Y chromosome. 
Presence of the Y chromosome, by contrast, 
triggers a cascade that differentiates the 
gonadal primordium into the testis and 
induces testicular gene expression in somatic 
cells. In the XX gonad or ovary, most of 
these genes are either not expressed or 
downregulated immediately beyond the 
undifferentiated bipotential stage [41]. 
Expression patterns of the essential genes in 
this process in the mouse are depicted in 
Figure 3; the function of these genes is 
discussed here based on the data obtained 
from mice, unless otherwise indicated. The 
initial switch in the testis cascade is the 
wave-like expression of Sry (sex-determining 
region of the Y chromosome) at E10.5-E12.5 
in the somatic cells of the indifferent gonad 
[42]. The role of Sry in mice was verified by 
forcing Sry expression in the somatic cells of 
Figure 2. Schematic presentation of the fetal 
gonads, the sex ducts, and their sexual 
differentiation.  The sex ducts, Wolfian and 
Müllerian, and the bipotential gonads arise 
from the mesonephros. The Y chromosome 
driven signaling cascade differentiates the 
gonad into the testis and promotes the 
development of the Wolfian derivates and the 
regression of the Müllerian ducts in males. In 
female, the ovary and the Müllerian duct 
derivates develop, while the Wolfian ducts 
regress. Adapted from [37].  
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XX gonads, which then resulted in a testis 
[43]. While the Sry gene was identified and 
characterized more than a decade ago 
[44,45], its molecular function is still poorly 
understood. Rather than directly activating 
gene expression, Sry may remodel the 
chromatin, thus facilitating specific gene 
expression [46]. Most probably, Sry 
contributes to the activation of Sox9 
expression, which in turn activates 
downstream genes in the testis cascade 
[47,48]. Although both Sry and the Sry-
related Sox9 possess an high mobility group 
box DNA-binding domain, only Sox9 seems 
to function as a transcription factor. Similarly 
to Sry, the introduction of Sox9 expression in 
XX gonads gives rise to a testis [49]. 
 
Anti-Müllerian hormone (AMH) 
The differentiating testis produces two 
hormones essential for male reproductive 
development: testosterone and anti-Müllerian 
hormone. The model of two testicular 
hormones causing sexual differentiation of 
the reproductive tract anlagen was first 
suggested by Dr. Jost in the 1940s [50,51]. 
His pioneering experiments in which a testis 
or a ovary was removed and then grafted 
onto male or female rabbits indicated that 
two testicular hormones were needed to 
enable male differentiation of the sex ducts. 
Years later, the specific inhibitory hormone 
for the Müllerian duct was purified and its 
cDNA isolated [52-54]. This important 
hormone has two equally common names: 
anti-Müllerian hormone (AMH) and 
Müllerian inhibiting substance (MIS); the 
name AMH is used in the present work, 
except in Study I. Experiments on mice, 
including null mutation and overexpression 
of the gene, have verified that AMH induces 
regression of the Müllerian duct in males, 
and represses Leydig cell proliferation and 
steroidogenesis in the testis [55-57]. 
Likewise, the absence of AMH in the female 
embryo allows the proper development of 
Müllerian duct derivates, i.e. the oviduct, 
uterus, and upper vagina. AMH is a 
homodimeric glycoprotein that belongs to the 
transforming growth factor β (TGF-β) 
superfamily, the members of which are 
involved at various points of growth and 
differentiation [58,59].  
 
TESTIS
Days post coitum
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Sox9
Wnt-4
DAX-1
SF-1
GATA-4 ? x     ?
AMH
UGR Indiff Fetal testis
Developmental stage
OVARY
Days post coitum
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Sox9
Wnt-4
DAX-1
SF-1
GATA-4 ? x     ?
AMH
UGR Indiff Fetal ovary
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Figure 3. Expression profiles of 
essential genes during gonadogenesis 
and sex determination. Gene 
expression in testicular and ovarian 
somatic cells presented at the fetal 
(nb, new born) developmental stages 
(UGR, urogenital ridge; indiff, 
indifferent, i.e. the bipotential 
gonad). Sox9, SF-1, and GATA-4 
directly activate the AMH promoter, 
whereas DAX-1 may modulate this 
action. Wnt4 is an extracellular 
signaling molecule, that works 
upstream of DAX-1. GATA-4 
expression in the early developmental 
stages is unknown. 
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As one might expect, AMH is expressed in a 
sexually dimorphic pattern in the gonads 
(Figure 3). In the testis, AMH is upregulated 
in the developing Sertoli cells immediately 
after the onset of testicular differentiation, 
whereas in the ovary AMH is only expressed 
in postnatal granulosa cells [60,61]. Given 
the AMH function, its fetal expression is 
under strict regulation and involves several 
factors [41,58,62]. Expression patterns of 
these genes in fetal gonads are, once again, 
dimorphic, accompanying AMH expression 
(Figure 3). Sox9, SF-1, and GATA-4 induce 
AMH by binding directly on the promoter 
[63,64], whereas DAX-1 more likely acts as 
a modulator of the SF-1 action [65]. The 
AMH action of Sox9 in fetal testis was 
elucidated by an engineered mutation in the 
Sox9 binding site of the AMH promoter. The 
mutation resulted in impaired AMH 
expression, testis formation, and Müllerian 
duct regression in XY mice [66]. Moreover, 
forced Sox9 expression in an XX mouse led 
to abnormal AMH induction and subsequent 
sex reversal of the female reproductive tract 
[49]. 
 
Steroidogenic factor 1 and GATA-4 
Steroidogenic factor 1 (SF-1) is widely 
involved in endocrine function in the 
pituitary gland, adrenals, and gonads [67]. 
SF-1 is an orphan nuclear receptor, acts as a 
transcription factor, and is readily expressed 
in the indifferent urogenital ridge at E9.0, 
prior to Sry, Sox9, and AMH [67,68]. Later, 
SF-1 expression is downregulated in the fetal 
ovary, but sustained in the testis (Figure 3). 
Null mutation of SF-1 results in gonadal and 
adrenal agenesis due to deterioration of the 
urogenital ridge and adrenal primordium by 
E12.5 through apoptosis [69]. These mice die 
within eight days after birth because of 
adrenocortical insufficiency. Subsequent 
studies have detailed that AMH upregulation 
in the testis is intimately associated with SF-
1 [68,70]. Mutation of the SF-1 binding site 
in the AMH promoter results in significantly 
reduced levels of AMH in male mice in vivo 
[66]. In these mice, AMH was, however, 
expressed in sufficient amounts to promote 
Müllerian regression; this did not occur when 
the Sox9 site was mutated. Interestingly, SF-
1 interacts directly with Sox9 [63], 
suggesting that the resulting synergism on 
the AMH promoter is essential to achieve 
high levels of AMH in the fetal testis.  
 
SF-1 has also been shown to physically 
interact with GATA-4 in order to 
synergistically activate AMH [35,64,71]. 
Although not verified in vivo, the proper 
GATA-4 action, the endogenous GATA-
4:SF-1 synergism, and the corresponding 
binding sites on the AMH promoter are 
essential for full AMH activity in cultured rat 
Sertoli cells [71,72]. Furthermore, the 
promoter of the SF-1 encoding gene, FTZF1, 
is activated by GATA-4 [73]. The GATA-4 
protein directly binds its target sequence on 
the FTZF1 and AMH promoters, and in the 
initial study [35] the GATA-4 expression 
pattern was found to be dimorphic in fetal 
gonads, resembling that of the other “testis 
genes” (Figure 3). This very likely benefits 
the activation of AMH expression by GATA-
4 in the fetal testis, as part of the 
transcriptional orchestration for AMH. 
Proper function and interaction of GATA-4 
and FOG-2 are required for normal male 
differentiation and for testicular gene 
expression, including expression of Sry, 
Sox9, and AMH [74]. 
 
2.3 Passive versus active signaling in the 
fetal ovary 
 
The old theory or dogma on passive 
differentiation of the gonadal primordium 
into the ovary in the absence of Y 
chromosome and testis-producing factors is 
losing its strength, as active signaling in the 
differentiating ovary has been demonstrated. 
In addition to the lack of AMH, the fetal 
ovary is devoid of androgen production. In 
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males, testosterone is required for the 
development of Wolfian duct derivates 
epididymides, vas deferens, and seminal 
vesicles (Figure 2). Leydig cell-produced 
testosterone also acts paracrinally in the testis 
and is required for the testes to descend.  In 
females, ectopic or abnormal levels of 
testosterone production by the gonads or 
adrenals lead to masculinization of the ovary 
and external genitalia, and thus the 
pseudohermaphroditism most commonly 
seen in congenital adrenal hyperplasia [75]. 
The ability to suppress fetal testosterone 
production is therefore essential for normal 
female development. Female development 
also requires proper estrogen function, given 
that mice null for estrogen receptors undergo 
postnatal sex reversal and abnormally 
express Sox9 and AMH [76]. Light has been 
shed on the mechanisms of “female 
signaling” via mouse models and findings in 
human disorders.  
 
Wnt4 and DAX-1 
Wnt4, a member of the wingless-related 
MMTV integration site family of locally 
acting secreted factors, has been determined 
to be essential for female reproductive 
development through studies on Wnt4-
deficient mice [40]. In its absence, the 
Müllerian duct fails to develop, while the 
Wolfian duct continues to develop. Even 
more importantly, the mice have 
masculinized ovaries with Leydig-like cells 
producing androgens and expressing the 
necessary steroidogenic enzymes [40]. In 
addition, macroscopically, the Wnt4-deficient 
ovary is round and resembles the testis. Thus, 
Wnt4 appears to be required to suppress 
Leydig cell development, testosterone 
production, and the resulting preservation of 
the Wolfian ducts by testosterone. External 
genitalia were not, however, virilized or 
masculinized in Wnt4-deficient mice. 
Subsequent studies have shown that Wnt4 is 
upstream of DAX-1 [77,78], a regulator able 
to repress SF-1-mediated promoter activation 
[65]. Not surprisingly, Wnt4 and DAX-1 are 
expressed in the bipotential stage, together 
with SF-1, but are downregulated in the testis 
at the onset of its differentiation (Figure 3). 
The picture recently became more complex, 
with results showing that in Wnt4-deficient 
mice the Sertoli cell differentiation in the 
fetal testis is compromised at least for a short 
while [79]. Interestingly, however, both the 
XY and XX gonads of Wnt4 deficient mice 
have increased numbers of steroidogenic 
cells [40,79]. 
 
DAX-1 is suggested to be an “ovarian-
determining” gene, given the human 
phenotype of genetically XY females who 
possess an extra copy of this X chromosomal 
gene [80]. Moreover, overly high levels of 
DAX-1 in mice, achieved by introduction of 
an extra DAX1, are able to antagonize the Sry 
action and retard testis differentiation [81], 
leading to the conclusion that DAX-1:SF-1 
dimer may repress testis genes such as Sox9. 
Likewise, Sry in the testis may prevent the 
DAX-1:SF-1 function [81]. In another mouse 
model, however, null mutation for DAX1 did 
not affect ovarian development or female 
fertility, instead abrogating postnatal 
spermatogenesis [82]. Thus, rather than being 
“ovarian-determining” genes, Wnt-4 and 
DAX-1 appear to be “anti-testis” or “anti-
male” factors in the ovarian cascade. 
Moreover, a given gene may act differently 
in humans and mice. Interestingly, DAX-1 is 
able to abrogate the SF-1:GATA-4 synergism 
on the AMH promoter [83]. Whether GATA-
4 has a role in the Wnt4 pathway remains 
unknown; the role of GATA factors in the 
development of the female reproductive tract 
also has not been addressed. 
 
2.4 Human reproductive tract 
development disorders 
 
Given the elaborate molecular mechanisms 
underlying the differentiation of the gonads 
and the sex ducts into male or female 
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reproductive organs, the process may 
sometimes be disrupted. Aberrations in the 
genes involved may cause complex 
developmental disorders, i.e. syndromes with 
gonadal dysgenesis, total or partial sex 
reversal of the reproductive tract, and/or 
dysgenesis in the organs derived from the sex 
ducts (Table 2). In general, most of the 
syndrome phenotypes have similarities with 
the corresponding genetic aberrations in the 
engineered mouse. 
 
Hitherto, three cases with mutations in the 
gene encoding SF-1 (FTZF1) have been 
demonstrated as the cause of 46,XY sex 
reversal with gonadal dysgenesis and adrenal 
insufficiency [85-88]. Two of these cases 
present with retained Müllerian duct 
derivates, indicating insufficient AMH 
production in fetal life; two of the mutations 
are heterozygous. Initially, the mutant SF-1 
protein (G35E; heterozygous) was found to 
have no dominant negative effect in in vitro 
gene expression assays, indicating that 
haploinsufficiency in FTZF1 causes the 
clinically severe phenotype [86,89]. 
However, subsequent in vitro analysis 
revealed that the mutated SF-1 protein 
(G35E) may act as a dominant negative 
competitor to the synergistic AMH activation 
by GATA-4 and SF-1 [90]. These findings 
suggest that proper GATA-4:SF-1 synergism 
is essential for human gonadal and adrenal 
development. 
 
The two sex chromosomes and the genes 
they possess clearly have a special role in 
human gonadal differentiation. First of all, 
SRY has a key role in determining testis 
development, whereas duplication of the X 
chromosomal DAX1 has been identified as 
the cause of the dosage-sensitive sex reversal 
syndrome [80]. Somewhat similarly to mice, 
XY individuals with an extra DAX1, develop 
as females, despite the presence of SRY 
[80,81]. On the other hand, mutations in 
DAX1 are associated with adrenal hypoplasia 
congenita, which is an X-linked syndrome 
   Table 2. Selected genes, the aberrations of which cause defects in human reproductive tract 
   development (adapted from tables in [75,84]). 
    AHC = adrenal hypoplasia congenita, HHG = hypogonadotropic hypogonadism 
Gene Location Protein and function Phenotype (M=mutation, D=duplication) 
SRY Yp11 Transcription factor M:  XY sex reversal, male gonadal dysgenesis; 
XX sex reversal in case of ectopic expression 
SOX9 17q24 Transcription factor M: Campomelic dysplasia, XY sex reversal, 
male gonadal dysgenesis D: XX sex reversal 
FTZF1 
(for SF-1)  
9q33 Nuclear receptor, 
transcription factor 
M: XY sex reversal, gonadal dysgenesis, 
adrenal insufficiency 
DAX1 Xp21.3 Nuclear receptor, 
transcription factor 
M: AHC, HHG   
D:  XY sex reversal, gonadal dysgenesis 
WNT-4 1p35 Wnt-type signaling 
molecule 
M: Müllerian agenesis/regression and 
androgen excess in female 
AMH 19q13 TGF- -type signaling 
molecule 
M: Persistent Müllerian duct syndrome in male 
AMHRII 12q12-13 Serine-threonine kinase 
receptor for AMH 
M: Persistent Müllerian duct syndrome in male 
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characterized by adrenal insufficiency and 
hypogonadism [91,92]. Intriguingly, most of 
these mutations abrogate the function of 
DAX-1 as a transcriptional repressor of SF-1 
[91]. Finally, aberrations in the other 
“ovarian-determining” or “anti-testis” gene, 
WNT4, have been associated with impaired 
development of the female reproductive tract. 
A recent report presented a loss of function 
mutation in WNT4 in a patient with primary 
amenorrhea, absent Müllerian duct derivates, 
and clinical signs of androgen excess [93]. 
This human phenotype has significant 
similarities with Wnt4-deficient mice [40] 
that exhibit failure in Müllerian duct 
development and masculinized androgen-
producing ovaries. Taken together, this data 
provides great insight into the genes and 
pathways essential for female development in 
mammals.
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3 Ovarian function 
 
3.1 Endocrine regulation of 
folliculogenesis 
 
The follicle, the major functional unit in the 
ovary, is regulated in a complex manner by 
both endocrine and paracrine components. 
The endocrine hormones are produced in the 
hypothalamus, i.e. gonadotropin-releasing 
hormone, and in the anterior pituitary, i.e. 
follicle-stimulating hormone (FSH) and 
luteinizing hormone (LH). In general, FSH 
and LH are secreted by the pituitary gland 
according to the phase of the menstrual 
cycle. Hormone production is regulated by 
direct feedback mechanisms from the 
gonads, which can be ectopically mimicked 
to suppress reproductive function. 
Suppression of gonadotropin secretion, and 
therefore folliculogenesis and ovulation, has 
been the main endocrine tool for female 
contraception for decades, while 
corresponding approaches for male 
contraception remain to be proven useful or 
reliable [94,95]. This section presents studies 
of both murine and human ovarian function. 
 
During fetal life, a pool of primordial 
follicles is formed as the somatic cells 
surround the oocytes (Figure 4). To some 
extent before birth, but more significantly at 
puberty, these quiescent follicles 
coordinately enter the growth phase as the 
oocyte increases in size and the squamous 
granulosa cells become cuboidal in order to 
form primary follicles. The oocyte continues 
to grow and granulosa cells proliferate; when 
two granulosa cell layers surround the 
oocyte, a theca cell layer is formed around 
the follicle. In the 1960’s, paracrine 
regulatory factors were shown to be required 
for folliculogenesis at the preantral follicle 
stage [96]; endocrine regulation becomes 
vital by the antral follicle stage. During 
antrum formation, the granulosa cells 
separate into two populations, i.e. cumulus 
cells immediately surrounding the oocyte and 
mural cells (Figure 4). In the last 
developmental stage, the dominant follicle is 
prepared to ovulate in each cycle.  
 
FSH and LH 
FSH is essential for ovarian function, 
upregulating a number of genes in granulosa 
cells [97,98], such as cyclin D2 involved in 
proliferation, inhibins that have both local 
and distant functions, aromatase enzyme 
required for estrogen production, and LH 
receptor (LHR), the expression of which 
precedes terminal differentiation of granulosa 
cells and ovulation. Correspondingly, FSH-
receptor (FSHR) expression is restricted to 
granulosa cells, whereas LHR is expressed in 
both theca and granulosa cells. The 
gonadotropins play key roles in the 
regulation of steroidogenesis; LH stimulates 
androgen synthesis in theca cells, and FSH 
induces estrogen conversion from the 
androgen substrate in granulosa cells. This 
model of gonadotropin function has been 
named “the two gonadotropin-two cell” 
Figure 4. Stages of folliculogenesis. 
Granulosa cells surrounding the oocyte are 
squamous at the primordial stage, but upon 
recruitment at the primary stage they 
become cuboidal. From the preantral stage 
onwards, theca cells surround the follicle 
(presented as flat cells in the preantral 
follicle; omitted in the illustration of the 
antral follicle). Antral follicles possess two 
granulosa cell populations, i.e. mural cells 
and cumulus cells, that surround the oocyte. 
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concept of estradiol production in the ovary 
[99]. In mice null for FSHR or LHR, the 
serum estradiol level is dramatically 
decreased, the uterus is atrophic, and the 
ovary is significantly decreased in size [100-
102]. The defects in folliculogenesis differ, 
however, between FSHR- and LHR-deficient 
mice. Both mice have no mature/ 
preovulatory follicles or luteal glands, but in 
FSHR-null mice the growth arrest is at the 
preantral stage [102], whereas in LHR-null 
mice it is at the antral stage [101]. These 
findings demonstrate the need for proper 
FSH action at the preantral stage and beyond, 
and LH action at the follicular maturation 
and ovulation stages.  
 
From the clinical point of view, mutations in 
either of these receptors have a direct 
implication on human reproductive function 
[103]. An inactivating mutation in LHR in a 
woman with a normal karyotype results in a 
relatively mild phenotype: normal primary 
and secondary sexual characteristics, but 
amenorrhea and low levels of estradiol [104]. 
Histologically, follicles of all stages, other 
than preovulatory follicles or a corpus 
luteum, were detected in the ovarian sample 
[104]. An inactivating mutation in FSHR has 
been linked with hypergonadotropic ovarian 
dysgenesis characterized by poorly 
developed secondary sexual characteristics, 
streak gonads, and primary amenorrhea 
[105]. Ovarian maturation at puberty is 
arrested by inadequate FSH action in the 
ovary, reflected as a high number of 
primordial and primary follicles, but only an 
occasional more-developed follicle [106]. 
 
Intracellular gonadotropin pathway 
In a given cell, the classical gonadotropin 
response employs G-proteins coupled with 
hormone receptor, adenylyl cyclase (AC), 
cyclic adenosine monophosphate (cAMP), 
and protein kinase A (PKA) (Figure 5). At 
the gene promoter level, the common signal 
mediator is the cAMP-responsive-element 
(CRE) that is bound by the phosphorylated 
CRE-binding protein (CREB). A number of 
gonadotropin- or cAMP-responsive genes, 
however, lack the consensus CRE site, and 
the response requires other endocrine cell-
specific transcription factors such as SF-1, 
GATA-4, or GATA-6 (Figure 5) [7,67]; all 
Figure 5. The classical intracellular pathway 
activated by gonadotropin FSH or LH. The solid 
upper line represents the cell membrane and the 
broken line the nuclear membrane. FSH binds its 
receptor FSHR, which couples with a G-protein 
(G). The activated G then activates adenylyl 
cyclase (AC), which produces the cyclic adenosine 
monophosphate (cAMP). cAMP binds the 
regulatory subunits  (R) of protein kinase A (PKA), 
which then localize into the nucleus and 
phosphorylate (P) the cAMP-responsive element 
(CRE) -binding protein (CREB). In addition, PKA 
is able to phosphorylate GATA-4 and SF-1, which 
together with CREB activate transcription of target 
genes in the nucleus. However, SF-1 is 
constitutively phosphorylated by other kinases, and 
its role in this cascade is not clear. 
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of these are expressed in murine gonads 
[34,36,67,107]. Similarly to AMH activation 
in the fetal testis, GATA-4 and SF-1 
synergistically activate genes for key 
enzymes in steroidogenesis [7,73]. 
Aromatase enzyme is needed to produce 
estrogens from the androgen substrate in 
granulosa cells. Furthermore, GATA-4 
mRNA is upregulated by FSH in the mouse 
granulosa and Sertoli cell tumor cell in vitro 
[36], but cAMP fails to upregulate GATA-4 
in primary rat Sertoli cells [108,109]. Instead, 
detailed in vitro analysis revealed that the 
GATA-4 function is activated in endocrine 
cells by phosphorylation of serine 261 by 
PKA in response to cAMP, depicting GATA-
4 as a novel downstream effector in this 
pathway [7,108,109]. Interestingly, the 
MAPK pathway, more specifically, the 
extracellular signal-regulated kinase (ERK), 
is activated independently of PKA in 
response to FSH, resulting in modulation of 
granulosa cell steroidogenesis [110,111]. It 
is, thus, evident that G-protein-coupled 
hormone receptors, like FSHR and LHR, also 
use other pathways besides the one 
connected to PKA [112]. 
 
3.2 Paracrine interplay between oocytes 
and granulosa and theca cells  
 
With no doubt about the critical roles played 
by endocrine gonadotropins in 
folliculogenesis, it has become evident that 
both the oocytes and the somatic cells 
produce a variety of paracrine factors 
affecting follicle development and 
modulating gonadotropin action [113,114]. 
In vitro studies utilizing follicle cultures 
show that follicular cells undergo 
luteinization if the oocyte is violently 
removed [96,115]. In addition, the oocyte 
supplies specific morphogens that preserve 
phenotype and gene expression in cumulus 
cells [113]. On the other hand, support by the 
follicular somatic cell is fundamental in 
providing the oocyte with the necessary 
nutrients and growth factors throughout 
folliculogenesis [116].  
 
Members of the TGF-β superfamily have 
essential roles in the paracrine interplay of 
ovarian cells. Growth and differentiating 
factor 9 (GDF9), bone-morphogenic protein 
15 (BMP-15; also known as GDF9B), and 
BMP6 are primarily oocyte-secreted [117-
120], while activins, inhibins, and AMH are 
expressed and secreted by somatic cells 
[61,121-123]. The corresponding receptors 
for these growth factors are differentially 
expressed in follicular cells, further fine-
tuning the three-cell interaction [123]. In 
general, the TGF-β signal in a given cell is 
mediated through specific serine/threonine 
kinase receptors expressed on the cell 
surface. The ligand-activated receptors 
phosphorylate the classical intracellular 
TGF-β signal mediators, the Smad proteins, 
which form complexes and localize to the 
nucleus to drive transcription of target genes 
together with cell-specific transcription 
factors [59]. To achieve functional diversity 
in cellular responses to TGF-β ligands, the 
corresponding receptors are able to activate 
kinases in a number of other pathways 
besides phosphorylation of Smads. As an 
example, the activated TGF-β receptors 
alternatively activate p38, a pivotal kinase in 
the MAPK pathway [124]. In addition, the 
Smad3/Smad4 complex is able to directly 
activate PKA [125]. 
 
Oocyte-derived GDF9 and BMP15 
Considerable progress has been made in the 
past decade in identifying critical oocyte 
factors. Of these, GDF9 is a cornerstone and 
is predominantly expressed in mammalian 
oocytes [113,117-119]. Mice null for Gdf9 
have abrogated reproductive function, 
reflecting hypergonadotropic hypogonadism 
with no antral follicles and no ovulation 
[126]. While organogenesis is normal, 
folliculogenesis arrests at a single layer of 
cuboidal granulosa cells with no theca. The 
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oocytes subsequently die and the somatic 
cells luteinize, resembling the findings in 
oocytectomized follicles [127]. Thus, GDF9 
may directly suppress FSH-dependent 
granulosa cell differentiation [128,129]. The 
mitogenic activity of GDF9 has been further 
studied by immunoneutralizing GDF9 in 
vitro to counteract its effect on granulosa 
cells [130]. This data indicated that GDF9 is 
powerful but not sufficient on its own to 
drive granulosa cell proliferation by the 
oocyte [130]. An additional mitogen could 
indeed be BMP15 (GDF9B), the lack of 
which causes only minimal ovarian 
histopathological defects, but a decreased 
ovulation rate [131]. Altogether, these findings 
suggest that GDF9 and BMP15 may work as 
heterodimers to synergistically regulate 
granulosa cell gene expression and 
proliferation, and subsequently, the ovulation 
rate. 
 
Inhibin 
Inhibin expression and production localizes 
to granulosa cells in the postnatal ovary 
[122]. The secreted inhibin A and inhibin B 
are heterodimers of a common α-subunit and 
βA- or βB-subunits, respectively. As 
endocrine hormones, the inhibins suppress 
production of FSH in the pituitary. In 
addition, accumulating evidence suggests 
that inhibins also play a paracrine role in the 
ovary [122,132]. Given that the supply of the 
α-subunit is critical for inhibin secretion, 
regulation of inhibin-α is fundamental and 
involves the endocrine FSH, the paracrine 
activin, and oocyte-derived factors [122,133]. 
Of the latter, GDF9 is one of the most likely 
mediators, stimulating inhibin production in 
human granulosa-luteal (GL) cells in vitro 
[134]. Cloning and further analysis of the 
inhibin-α promoter have demonstrated 
specific targets for transcriptional regulators, 
e.g. sites for CREB, estrogen receptors, SF-1, 
and GATA-4 [34,135,136]. Moreover, 
identification of the synergistic and cAMP-
activated effects of CREB and SF-1, as well 
as of GATA-4 and SF-1, has shed light on 
inhibin-α regulation at the promoter level 
[73,135].  
 
AMH 
In addition to its essential role in sexual 
differentiation of the reproductive tract, 
AMH is a granulosa cell product capable of 
suppressing the follicular growth induced by 
FSH and epidermal growth factor [121,137-
141]. The Amh-null mice have an increased 
number of follicles committed to grow, 
resulting in loss of the primordial follicle 
pool at a premature age [139,141]. Taken 
together, the results suggest that AMH is 
involved in suppressing primary growth 
recruitment of primordial follicles, most 
likely through autocrine action on granulosa 
cells [142]. As is the case in testicular Leydig 
cells [55,143], AMH may also suppress 
steroidogenesis in the ovary [137], e.g. by 
abrogating PKA-induced enzyme expression 
[143]. Regulation of AMH in postnatal 
testicular Sertoli cells differs somewhat from 
that in the fetal testis and requires FSH action 
through cAMP on a distal enhancer at -3068 
bp of the AMH promoter [144,145]. In the 
fetal testis, the more proximal -180 bp 
promoter is sufficient to promote AMH 
expression [70]. Most recent studies show 
that the oocyte also contributes to AMH 
regulation in granulosa cells [146], thus 
having remarkable similarities to inhibin-α 
regulation. In addition, both of these genes 
are direct targets for SF-1 and GATA 
proteins [35,73,135].  
 
AMH is evolving as a potent serum marker 
for ovarian reserve. In normo-ovulatory 
women, AMH serum levels decrease with 
advancing age, concomitant with a decrease 
in the number of antral follicles [147]. In 
anovulatory women with fertility problems 
this decline is, however, less obvious, 
suggesting an increased ovarian reserve and 
delayed ovarian aging [148,149]. With 
respect to assisted reproduction by in vitro 
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fertilization (IVF), AMH measurements may 
have prognostic value in evaluating the 
outcome of a given pregnancy [150,151]. 
Additional clinical implications for AMH 
include use as a marker for follow-up and as 
a chemotherapeutic agent in cancer. 
 
3.3 Granulosa cell proliferation 
 
Proliferation of granulosa cells is a key 
component in folliculogenesis and is 
regulated by endocrine, paracrine, and 
autocrine factors during each ovulatory cycle 
(Figure 6) [97,98]. Accordingly, oocyte-
derived factors, FSH, and estrogens are the 
main players in this orchestra. Follicular 
growth is arrested in mice deficient in FSH 
or FSHR [100,152]. Of the FSH-activated 
genes, cyclin D2 is of special interest given 
that its null mutation in mice leads to 
impaired granulosa cell proliferation in 
response to FSH [153]. In brief, the cell cycle 
is regulated by cyclin-dependent protein 
kinases that couple with the cyclin proteins to 
activate downstream processes and DNA 
replication. In the G1 phase of the cell cycle, 
preceding the DNA replication phase, the D-
type cyclins are critical in controlling the 
cell-cycle clock. Of the D-type cyclins, 
cyclin D2 appears to be essential and specific 
for granulosa cells [98,153]. The 
upregulation of cyclin D2 by FSH also 
involves ERK [154]. The molecular 
mechanisms at the cyclin D2 promoter are 
starting to unravel, involving at least the 
forkhead transcription factor FOXO1 and 
Smad proteins activated by activins [155]. 
The cyclin D2 promoter also contains 
consensus GATA-binding site(s) [156,157], 
and the ERK pathway and GATA-4 activate 
cyclin D2 expression and proliferation at 
least in pulmonary cells [158]. In women, the 
inactivating mutation of the FSHR 
interestingly leads to an arrest of 
folliculogenesis [105,106], which among 
other possibilities may be connected to 
abrogation of cyclin D2-dependent 
proliferation. 
Figure 6. Schematic summary of 
signaling cascades regulating 
expression of granulosa cell genes 
involved in proliferation. Granulosa 
cells and oocytes secrete 
paracrine/autocrine ligands of the TGF-
β family (e.g. activin, inhibin, AMH, 
TGF-β, and GDF9); ligands for the 
mitogen-activated protein kinase 
(MAPK) pathway are not presented 
here. However, FSHR and TGF-β 
receptors (types II and I) activate ERK 
and p38, kinases of the MAPK pathway. 
The classic TGF-β response involves 
phosphorylation of the Smad proteins, 
which localize to the nucleus to act as 
transcription factors. All of these 
pathways are involved in regulation of 
LH receptor (LHR), cyclin D2, 
aromatase, and secreted inhibin and 
AMH. 
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The autocrine factors activin, inhibin, and 
AMH have also been implicated in granulosa 
cell proliferation. Activin has a key role in 
promoting proliferation and potentiates the 
action of FSH by, for example, upregulating 
FSHR, while inhibin may antagonize the 
mitogenic effects of activin and possibly 
GDF9 [122,123,159]. Although the 
underlying molecular mechanisms are not 
fully known, AMH inhibits proliferation by 
suppressing the function of FSH and growth 
factors and the initial growth of the follicles 
[58,142]. The role of the oocytes is 
remarkable in that it activates granulosa cell 
proliferation as well as expression of inhibin 
and AMH, i.e. suppressors of proliferation. 
Oocyte signals are essential for FSH-
independent granulosa cell proliferation in 
primary- and preantral-stage follicles 
[113,114]. Oocyte-derived GDF9 is critical 
for proliferation in view of the follicular 
growth arrest in Gdf9-deficient mice and the 
ability of GDF9 to directly stimulate DNA 
synthesis [126,129]. All in all, mechanisms 
integrating the fundamental but complex 
autocrine and oocyte signals in granulosa 
cells are just starting to become to unraveled. 
 
3.4 Apoptosis in the ovary 
 
Granulosa cells constantly proliferate during 
folliculogenesis and in each menstrual cycle. 
The preovulatory dominant follicle is, 
however, the tip of the iceberg as to the 
number of follicles recruited to growth. If the 
follicles were not adequately disposed of, the 
ovary would eventually fill the 
retroperitoneum with granulosa cell masses. 
Thus, self-controlled death by apoptosis is 
the inevitable endpoint of most of the 
follicles. In postnatal life, apoptosis is 
prominent in the somatic cells of atretic 
follicles [160], whereas in fetal life a great 
number of the newly developed oocytes 
undergo apoptosis [161]. In both the fetal and 
adult ovary, apoptosis is regulated by 
members of the Bcl-2 family and executed by 
caspase enzymes. The cyclic recruitment by 
FSH is key in rescuing preantral and antral 
follicles from undergoing apoptosis [162]. 
On the other hand, reduction in activity of the 
ERK pathway due to withdrawal of tropic 
hormone FSH is involved in committing the 
follicles to apoptosis [163]. The sex 
hormones seem to have adverse effects on 
granulosa cells in this respect; androgens 
promote apoptosis, while estrogens inhibit 
the action [164]. The initial study of GATA-
4 expression in the mouse ovary interestingly 
suggested that GATA-4 would protect 
granulosa cells from undergoing apoptosis 
[36]. This role for GATA-4 has been 
supported by findings in the mouse heart, in 
which GATA-4 is capable of protecting the 
cardiac cells against cytostatic-induced 
apoptosis [165]. The underlying molecular 
mechanisms are connected to direct 
upregulation of anti-apoptotic gene Bcl-X by 
GATA-4 [165]. 
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4 Ovarian granulosa cell tumors 
 
4.1 Incidence and clinical characteristics 
 
Ovarian cancer is the fourth-ranking 
malignancy in women in Finland. Granulosa 
cell tumors (GCTs) are the most common 
representative of the group of sex cord 
stromal tumors of the ovary, accounting for 
5% of all ovarian cancers [166]. As the 
group’s name indicates, these tumors are 
derived from somatic stromal cells of the 
gonad. The incidence of GCTs ranges from 4 
to 17 cases per million worldwide, with 
peaks occurring at late reproductive age and 
menopause [167-172]. In Finland, GCT 
incidence has been reported to be from 4.7 to 
8.7 cases per million, varying somewhat 
from one decade to another due to alterations 
in use of hormone treatments [172]. GCTs 
can occur at any age and in both sexes. In 
contrast to the predominant adult subtype of 
GCT, a juvenile subtype is usually diagnosed 
in children and adolescents [173,174]. This 
diagnosis is, however, mainly based on 
tumor morphology rather than age of the 
patient. 
 
Excessive hormonal activity of tumor cells 
and overproduction of estrogens and inhibins 
are the biological features most frequently 
causing the clinical signs and symptoms of a 
GCT, both prior to menarche and in 
adulthood (Table 3) [175-178]. Juvenile GCT 
is one of the main causes of precocious 
puberty [173,174]. At post-menarche, various 
disturbances in the menstrual cycle, 
including prolonged fertility problems [178], 
usually lead to reference to a clinic. GCTs 
can also be discovered microscopically, e.g. 
as a secondary finding to an endometrial 
hyperplasia or carcinoma in the uterus 
[176,177]. Oftentimes, GCTs are 
hemorrhagic and large, >10-15 cm in 
  Table 3. Typical clinicopathological characteristics of human granulosa cell tumors (summarized  
  from [177-181]). 
 
Selected granulosa cell tumor characteristics Notes 
     Signs and symptoms   
   
  
Precocious puberty, secondary amenorrhea, 
meno-metrorrhagia, postmenopausal 
bleeding, infertility, endometrial hyperplasia 
or cancer, abdominal pain 
 
 
Pathologic features     
Gross appearance   
  
Large (>10 cm), solid, cystic, hemorrhagic, 
“tan-yellow” (indicating steroid production)  
May present in 
microscopic size 
Microscopic   
   
  
Small, round, or oval granulosa cells with 
“coffee bean”-like uniform nuclei; variety of 
histological patterns (see text); nuclear atypia 
rate and mitotic index usually low  
 
May also have 
similarities with 
undifferentiated 
carcinoma 
 Inhibin-   Positive (in most cells) Immunohistochemical 
markers  Epithelial membrane antigen  Negative (usually) 
  Calretinin (a mesothelial marker)  Positive (usually) 
  Anti-Müllerian hormone  Positive (diffusely) 
  CD99  Positive (in some cells) 
  Melan-A (a melanocytic marker)  Positive  
(in steroidogenic cells) 
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diameter, manifesting as painful abdominal 
mass [167,170,175]. 
 
4.2 Diagnosis, treatment, and prognosis 
 
Although the signs and symptoms often give 
clues, GCT diagnosis is typically made at 
surgery in conjunction with an intra-
operative assessment by a pathologist. 
Subsequent morphological analysis coupled 
with immunohistochemical markers aims at 
verifying the diagnosis (Table 3). The 
operation strategy depends on the clinical 
stage of the tumor and the patient’s age and 
wishes to preserve fertility [176,177]. In 
postmenopausal women, a radical 
hysterectomy, including bilateral 
ovariectomy, is recommended even for stage 
I tumors. If fertility is to be preserved, only 
the diseased ovary is removed and lymph 
node biopsies performed. Adjuvant treatment 
is less commonly considered, as most of the 
tumors present at an early clinical stage 
(stage Ia). The chemotherapeutic approach 
has given varying results; whether an 
individual patient benefits from adjuvant 
therapy remains unclear, except for in the 
rare case of spread disease [176,177]. 
 
In contrast to epithelial ovarian cancer, GCTs 
are considered of to be of low malignant 
potential. The 10-year survival rate is 
favorable, varying from 60% to 95% 
[167,168,173,182,183]. However, GCTs 
have a high risk of long-term recurrence, 
even multiple recurrences, and may reappear 
as late as 37 years after the primary diagnosis 
and treatment [171,175,184]. Furthermore, 
even a microscopic primary tumor has been 
documented to present with a 20-cm-sized 
recurrence after six years [185]. These 
peculiar features and the limited prognostic 
tools challenge the clinicians when 
evaluating prognosis at diagnosis. None of 
the available tissue markers are proven useful 
for evaluating prognosis, leaving the clinical 
stage as one of the only tools in clinical 
practice. This stage has, however, significant 
limitations since the guidelines set for 
clinical staging of ovarian cancer by the 
International Federation of Gynecology and 
Obstetrics (FIGO) have been primarily 
designed for the most common epithelial 
ovarian cancers.  
 
4.3 Pathologic and cytogenetic 
characteristics 
 
The sex cord stromal tumors have similarities 
and differences in the two gonads. In 
addition to GCTs of adult and juvenile type, 
they include Sertoli cell tumors, Sertoli-
Leydig cell tumors, theca cell tumors (i.e. 
thecomas), and a group of unclassified 
tumors [166,181]. The typical characteristics 
of ovarian GCTs are summarized in Table 3. 
The histological patterns of GCTs include 
micro- or macrofollicular, tubular, trabecular, 
and insular variants, which together can be 
considered morphologically as a 
differentiated type. Some of the tumors are of 
a diffuse or sarcomatoid type that 
occasionally can be misdiagnosed as an 
undifferentiated carcinoma, especially at an 
intraoperative assessment of a frozen section 
[177,181]. In general, the pathologic features 
of GCTs resemble other types of more 
benign cancers. Mitotic index (MI) coupled 
with Ki67 staining, an 
immunohistochemically detected marker of 
proliferating cells, often depict a low rate of 
mitosis in GCTs [166]. This is consistent 
with the indolent and slow growth potential 
of these tumors. Oddly, despite the low MI, 
GCTs at diagnosis tend to be large. 
 
Tumor cell nuclei typically have a low atypia 
rate, suggesting the absence of complex 
genomic alterations. Nevertheless, a few 
common but nonobligatory cytogenetic 
changes have been detected in GCTs, 
including trisomy 12, trisomy 14, and 
monosomy 22 [186-190], and partial or 
complete gains in e.g. chromosomes 8, 9, and 
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15 [190]. While all of these areas contain 
genes for putative oncogenes or tumor 
suppressors, whether the gains or losses 
impact the level of gene expression has not 
been addressed. Epigenetic changes, such as 
alterations in methylation rate of gene 
promoters, may underlie the cytogenetic 
changes in cancer. Reduced expression of 
DNA methyl transferase, for instance, may 
cause chromosomal instability by genome-
wide hypomethylation [191]. On the other 
hand, hypermethylation of specific gene 
promoters has beenshown to inactivate 
genes, such as tumor suppressor genes, a 
finding also reported in GCTs [188,189,192]. 
 
4.4 Molecular pathogenesis: 
dysregulation of normal      
granulosa cell function? 
 
The characteristics of GCT cells closely 
resemble those of the proliferating granulosa 
cells in growing follicles and express many 
of the (normal) granulosa cell genes that have 
key roles in folliculogenesis [153,193-195]. 
The preserved granulosa cell function allows 
ongoing hormone production by the tumor 
cells. Although the specific events in GCT 
pathogenesis remain obscure, misregulation 
of granulosa cell proliferation and apoptosis 
is considered to inevitably contribute to the 
malignant transformation of granulosa cells 
and the development of a long-latency GCT 
[196,197]. Some defects behind the improper 
proliferation have indeed been highlighted 
during recent years. The regulatory factors, 
the normal functions of which are presented 
in Figure 6, are discussed below. 
 
FSH and cyclin D2 
Overactivity in the FSH signaling cascade is 
one of the leading hypotheses for GCT 
pathogenesis. FSHR and cyclin D2 
expression has been shown to be strong in 
human GCTs [153,194]. Previous attempts 
have, however, failed to identify (activating) 
mutations in the FSHR or in the downstream 
effectors of the cascade, e.g. in G-protein, 
PKA, or CREB [196,198-200]; the role of 
GATA-4 has remained unaddressed. In 
mouse models, FSH deficiency is able to 
reduce the growth rate or penetrance of 
GCTs [201,202]. Of interest in this respect, 
the GCTs have a peak in incidence at late 
reproductive age and around menopause 
[177]. The serum gonadotropin levels at this 
time are high, which could aid the escape of 
a subpopulation of follicular cells from the 
normal cell cycle control, e.g. by inadequate 
activation of the FSH target genes. Recent 
studies have further supported the 
hypothesis, that cyclin D2 is key in 
promoting gonadal tumorigenesis [192,203]. 
 
MAPK, TGF-β, and Wnt signaling 
In addition to FSH, mitogenic signaling 
through the MAPK, TGF-β, and Wnt 
pathways may promote the malignant 
transformation of granulosa cells. In fact, 
ERK (part of the MAPK system) has been 
found in an active state in in vitro cultured 
human GCT cells derived from a recurrent 
GCT, as well as in most aggressive primary 
GCTs studied [204]. This finding is 
consistent with the connections of FSH 
cascade and ERK to granulosa cell 
proliferation [154]. Mutations in the 
components of the TGF-β cascade have been 
found in a number of human cancers, e.g. 
loss of function of Smad4 in pancreatic 
cancer (the gene formerly named DPC4: 
Deleted in Pancreatic Cancer 4) [205,206]. In 
one study of serous ovarian carcinomas, one-
third of the tumors had very weak or no 
expression of Smad2 or Smad4 proteins 
[207]; the role of the TGF-β cascade in 
human GCT is largely unaddressed, except 
for inhibin (see below). Interestingly, the 
Wnt pathway has also recently been 
associated with ovarian tumorigenesis. 
Overexpression of its intracellular effector 
molecule β-catenin is tumorigenic in the 
mouse ovary; although not literally a GCT, 
the resulting tumors have characteristics 
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similar to GCTs (D. Boerboom, pers. comm. 
2004). Whether the Wnt pathway and β-
catenin have an impact on human GCTs 
remains unknown [197]. 
 
Inhibin and AMH 
Loss of normal growth suppressors could 
further enhance granulosa cell proliferation. 
In the mouse, loss-of-function studies have 
revealed inhibin-α to be a tumor suppressor 
gene since the null mice develop sex cord 
stromal tumors, including ovarian GCTs 
[203,209]. In women, however, GCTs 
express inhibin-α [195,210,211], which is a 
key diagnostic marker in surgical pathology 
[181,212]. Furthermore, the GCT-secreted 
inhibin is utilized as a serum marker in 
patient follow-up [213,214]. The role of 
inhibin-α as a tumor suppressor in human 
GCT pathogenesis is, thus, constantly under 
debate. Lastly, AMH also has been 
implicated as a tissue and serum marker for 
GCTs as well as for Sertoli cell tumors. 
AMH is reported to be diffusely expressed in 
GCTs [179,210], and with the use of serum 
AMH measurements a recurrence has been 
detected 11 months prior to clinical 
presentation [215,216]. Mice deficient for 
both inhibin-α and Amh develop ovarian sex 
cord stromal tumors similar to those in 
inhibin-α-null animals [217], whereas mice 
deficient for only Amh have no reported 
ovarian tumors. Given the putative role of 
AMH as a suppressor of granulosa cell 
proliferation [139-141], reduced or lost AMH 
production could allow GCT development by 
abolishing local growth suppression. 
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AIMS OF THE STUDY 
 
Normal ovarian development and function require specific transcriptional regulation. Previous 
studies have elucidated the expression and function of transcription factors GATA-4 and GATA-
6, along with adrenal, testicular, and cardiac development. These factors are also expressed in the 
mouse ovary. Furthermore, GATA-4 has been depicted as an effector in the gonadotropin-
activated cascade in endocrine cells. Based on the hypothesis that GATA transcription factors 
play a role in the mammalian ovary, this study was designed to determine the impact of GATA-4, 
GATA-6, and cofactor FOG-2 on human ovarian development, function, and tumorigenesis. 
Specific aims of this series of studies were: 
 
 
1) To profile the expression of GATA-4, GATA-6, and their cofactor FOG-2 in the mouse 
and human ovary during fetal development and postnatal folliculogenesis. 
 
2) To analyze how GATA-4, GATA-6, and FOG-2 affect ovarian development and function 
by studying the regulation of their expression as well as their role in activating 
downstream target genes inhibin-α and anti-Müllerian hormone in ovarian cells. 
 
3) To determine whether GATA-4, GATA-6, FOG-2, and anti-Müllerian hormone have an 
impact on malignant proliferation of ovarian granulosa cells and on clinical behavior of 
granulosa cell tumors. 
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MATERIALS AND METHODS 
 
1 Patients and clinical data (IV) 
 
Study IV consists of 80 female patients 
diagnosed as having GCT at the Department 
of Obstetrics and Gynecology, Helsinki 
University Central Hospital, between 1971 
and 2003. The patients were identified from 
the archives of the Department of Pathology, 
and available paraffin-embedded tissue 
samples were re-evaluated for GCT diagnosis 
by a gynecologic pathologist. The 
clinicopathologic data of tumor patients were 
retrospectively scrutinized from patient files, 
and data on survival were confirmed with the 
Central Statistical Office of Finland. Clinical 
stage was determined according to the 
classification scheme of FIGO. After primary 
surgery, the patients had been routinely 
monitored by at least yearly visits. Detection 
of late recurrences was possible since 
treatment of GCTs in the district is 
centralized to the tertiary university hospital; 
a few patients were tracked from other 
central hospitals. The study protocol was 
approved by the Ethics Committee of the 
University of Helsinki and by the National 
Authority for Medicolegal Affairs in Finland 
(TEO). 
 
2 Tissue samples (I-IV) 
 
2.1 Mouse (I) 
 
All animal studies were conducted in 
accordance with the NIH Guide for the Care 
and Use of Laboratory Animals. Gonads of 
strain CBA or NMRI mice were dissected on 
embryonic days (E) 12.5, 13.5, 15.5, and 
17.5, and on postnatal days 1, 7, 14, 25, and 
60; E10 embryos were used entirely. The 
samples were snap-frozen or fixed in 4% 
paraformaldehyde and embedded in paraffin. 
Sex of day 10 and 12 embryos was 
determined by PCR analysis for the Sry gene 
on genomic DNA [218]. 
 
2.2 Normal human ovary (II-IV) 
 
Ovaries from eight fetuses (age 13–22 and 33 
weeks) with normal karyotype were obtained 
after spontaneous or therapeutic abortions 
because of maternal disease, and from six 
neonates (fetal age 23–39 weeks at birth) 
who died within 48 h of birth because of 
perinatal asphyxia or infection. Adult ovarian 
tissue samples were obtained from women 
(age 22–45 years) undergoing ovariectomy 
because of either uterine myomas (n = 4) or 
focal endometrial cancer (n = 4) in Study II, 
and because of cervical cancer without 
preoperative irradiation (n = 4) in Study III. 
In addition, normal ovarian samples (n = 3), 
removed because of cervical cancer (patients’ 
age <35 years), were used as normal 
reference tissue in Study IV. The samples 
were fixed in 4% buffered formaldehyde (II) 
or formalin (III and IV) and embedded in 
paraffin for histological analyses, in situ 
hybridization, and immunohistochemistry, or 
snap-frozen and stored at -70ºC for RNA 
extraction and Northern blot analysis (II and 
III). These studies were approved by the 
local Ethics Committees of the Universities 
of Oulu and Helsinki. 
 
2.3 Human tumor samples and tissue 
microarray (III, IV) 
 
For mRNA analysis (III), tumor samples 
were obtained from 24 women who 
underwent surgery for either GCT (n=15) or 
thecoma (n=9) at the Department of 
Obstetrics and Gynecology, Helsinki 
University Central Hospital. In addition, the 
tumor samples of the 80 GCT patients (IV) 
were subtyped and evaluated for the degree 
of nuclear atypia by a gynecologic 
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pathologist according to established criteria 
[219]. Tumors having micro- or 
macrofollicular, tubular, trabecular, and 
insular characteristics were considered a 
differentiated subtype (n=56), separate from 
more diffuse (sarcomatoid) tumors (n=24). 
From each tumor, four areas with the highest 
mitotic activity were sought, and the number 
of mitotic figures in ten high-power fields 
was counted in each to establish the mitotic 
index (MI; cut-off low or high). A tissue 
microarray was constructed from the samples 
as described previously [220]. In brief, four 
core tissue biopsies were obtained from each 
of the 80 primary GCTs, and the specimens 
were arranged in one recipient paraffin block.  
 
3 Cell cultures (I, III) 
 
3.1 Cell lines and transient   
transfections (I) 
 
293T, COS-7, NIH 3T3, and KK-1 cells were 
cultured using DMEM, supplemented with 
10% fetal bovine serum and antibiotics 
(Gibco, Grand Island, NY, USA). The KK-1 
mouse granulosa cell line was established 
from the ovarian tumor of inhibin-α 
promoter-driven SV40-T-antigen transgenic 
mice [221]. Twenty-four hours before 
transfection, the cells were plated on 12- or 
6-well dishes. KK-1 cells were transfected 
with Lipofectamine or Lipofectamine 2000 
(Gibco BRL, Grand Island, NY, USA), and 
the other cells with FUGENE6 (Roche 
Molecular Biochemicals, Mannheim, 
Germany), with minor modifications to the 
manufacturers’ protocols. The transfected 
plasmids included the luciferase reporter-
coupled promoters of MIS [70], wildtype 
inhibin-α, and inhibin-α with mutated 
GATA-binding sites [34], as well as the 
expression vectors for GATA-4 [222], and 
FOG-2 [12]. In the inhibin-α−luciferase 
plasmids, the original pTKGH reporter 
plasmid [34] was replaced with pGL2 by 
subcloning to the Hind III sites and thereafter 
by sequencing to verify orientation. In all 
experiments, pCMVβ (Clontech, Palo Alto, 
CA, USA), a β-galactosidase expression 
vector, was cotransfected to monitor 
transfection efficiency. The inhibin-α 
promoter-transfected cells were stimulated 
with recombinant TGF-β (R&D Systems, 
Minneapolis, MN, USA) for 24 h prior to 
harvest, which was carried out 40-48 h after 
transfections in all assays. The determined 
luciferase-enzyme activity was normalized to 
the β-galactosidase activity, and each 
experiment was performed in triplicate at 
least three times to ensure reproducibility. 
The results were presented as mean ± 
standard error of three independent 
experiments. 
 
3.2 Human granulosa-luteal cell culture 
and treatments (III) 
 
Human granulosa-luteal (GL) cells were 
obtained by follicular aspiration from 
regularly menstruating women undergoing 
oocyte retrieval for IVF. In ovarian-
hyperstimulated patients, the oocyte retrieval 
was carried out 36-37 h after human 
chorionic-gonadotropin (hCG) 
administration. For the in vitro experiment, 
the cells from two to four patients were 
pooled, enzymatically dispersed, and 
separated as previously described [223]. The 
cells were then recovered for RNA extraction 
or plated at a density of 2-5 x 105 cells/well 
on six-well dishes, and cultured in DMEM 
supplemented with 10% fetal calf serum, 2 
mM L-glutamine, and antibiotics (Gibco). 
Hormone treatments were performed 
between days 3 and 7 of culture for different 
time periods. Before treatments, the cells 
were transferred to DMEM supplemented 
with 2.5% fetal calf serum. The cells were 
treated with 30 ng/ml of recombinant human 
FSH (rhFSH) (Organon International BV, 
Oss, The Netherlands), 30 or 100 ng/ml of 
purified hCG (obtained from the National 
Hormone and Pituitary Distribution Program, 
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NIDDK, NIH), or 0.5-1.0 mM 8-bromo-
cAMP (8-Br-cAMP) (Sigma Chemical Co., 
St. Louis, MO, USA). Each experiment was 
performed at least three times with duplicate 
or triplicate cultures to ensure 
reproducibility. 
 
4 mRNA expression (I-IV) 
 
4.1 Cloning of human GATA-4,     
GATA-6, and FOG-2 cDNAs          
for templates (III) 
 
Human 575-bp GATA-4, 712-bp GATA-6, 
and 342-bp FOG-2 cDNAs were synthesized 
by RT-PCR from human GL cell RNA using 
specifically designed oligonucleotides: for 
GATA-4, 5’-CTC-CTT-CAG-GCA-GTG-
AGA-GC and 5’-GAG-ATG-CAG-TGT-
GCT-CGT-GC (GenBank accession no. 
NM002052); for GATA-6, 5’-ATG-ACT-
CCA-ACT-TCC-ACC-TCT and 5’-CAG-
CCT-CCA-GAG-ATG-TGT-AC (GenBank 
accession no. NM005257); for FOG-2, 5´-
CAG-AGT-CGA-CAG-CAA-CTT-CC and 
5´-GCC-TGC-TGG-ACT-CAA-TTC-AG 
(GenBank accession no. AA975109). The 
GATA-4 and GATA-6 cDNAs were 
subcloned into the pGEM-7Zf(+/-) vector 
(Promega, Madison, WI, USA), and the 
FOG-2 cDNA into the pGEM-T Easy vector 
(Promega), and sequenced to verify the 
sequence and orientation.  
 
4.2 RNA extracts and                  
Northern analysis (I-III) 
 
Total cellular RNA was extracted by the 
guanidine isothiocyanate-cesium chloride 
method [224] or by a commercial kit 
(RNeasy cat# 74104, Qiagen, Hilden, 
Germany), quantified by absorbance at 260 
nm, size-fractionated in 1.5% agarose-
formaldehyde, and transferred to a Biodyne 
Transfer membrane (Pall Europe Ltd., 
Portsmouth, England). The filter was UV-
cross-linked prior to hybridization. cDNA 
probes were synthesized from templates 
(Table 4) with a Prime-a gene kit (Promega) 
and labeled with [32P]- -deoxy-CTP (3000 
Ci/mmol; Amersham, Arlington Heights, IL, 
USA). The probes were purified with Nuck 
Trap columns (Stratagene, La Jolla, CA) or 
with Nick columns (Pharmacia, Uppsala, 
Sweden) and used at 1–3 x 106 dpm/ml in 
hybridization solution containing 50% 
formamide, 6 x SSC buffer, 0.1% Ficoll, 0.1% 
polyvinylpyrrolidone, 0.1% bovine serum 
albumine, 100 g of salmon sperm DNA/ml, 
100 g of yeast RNA/ml, and 0.5% SDS. 
Northern blot filters were hybridized for 16 h 
at 42ºC, washed with 1 x SSC-0.1% SDS, and 
exposed to X-ray films with Trimax 
intensifying screens (3M, Ferrania, Italy) at -
70°C.  
 
4.3 In situ analysis (I-IV) 
 
Paraffin-embedded sections were 
deparaffinized in xylene, rehydrated in 
decreasing alcohol series, and treated with 
proteinase-K (Sigma) before hybridization. 
The sections were subjected to in situ 
hybridization as described elsewhere [225] 
with some modifications. The tissue sections 
were washed in PBS, acetylated, dehydrated, 
and then incubated with 1 x 106 cpm of [32P]-
labeled (1000 Ci/mmol; Amersham) 
antisense and sense riboprobes (Table 4) in a 
total volume of 80 µl at 60°C for 18 h. After 
washes, RNA digestion, and dehydration, the 
sections were dipped in NTB2 nuclear 
emulsion (Kodak, Rochester, NY, USA) and 
exposed in the dark at 4°C for 1 or 2 weeks. 
After developing, the sections were 
counterstained with hematoxylin and eosin. 
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5 Protein expression (I-IV) 
 
5.1 Nuclear protein extracts and 
Western analysis 
 
KK-1 cells were stimulated with recombinant 
TGF-β (R&D Systems), harvested, and the 
nuclear proteins extracted as described 
previously [226], employing two steps with 
two lysis buffers on ice; first for 15 min with 
10 mM Hepes, 1.5 mM MgCl2, 10 mM 
KCL, 1 mM dithiotreitol, 0.5 mM PMSF, and 
a protease inhibitor cocktail, followed by 
rapid centrifugation to pellet the nuclei; 
second for 20 min with 10 mM Hepes, 15% 
(vol/vol) glycerol, 1.5 mM MgCl2, 0.2 mM 
EDTA, 420 mM NaCl, 1 mM dithiotreitol, 
0.5 mM PMSF, and a protease inhibitor 
cocktail, followed by rapid centrifugation to 
pellet the nuclear debris. Protein aliquots of 
40 µg were subsequently separated by 7.5% 
SDS-PAGE and transferred to Immobilon-P 
membrane (Millipore, Bedford, MA, USA). 
The nonspecific antibody binding on the 
membrane was blocked with 5% skim milk 
in 0.1% Tween-TBS buffer, and GATA-4 or 
control Actin proteins were detected with 
primary antibodies (Table 4) for 1 h at room 
temperature followed by a secondary 
antibody (Jackson Laboratories, West Grove, 
PA, USA), and then visualized by an 
enhanced chemiluminescence plus kit 
(Amersham Biosciences, Buckinhamshire, 
UK). 
 
5.2 Immunohistochemistry (I-IV) 
 
Paraffin-embedded sections were 
deparaffinized, hydrated, and treated with 10 
mmol/l citric acid in a microwave oven for 
  Table 4.   Probes and antibodies used in the study. 
  * Indicates mouse (m) or human (h) studies; IHC = immunohistochemistry, NB = Northern blotting, 
     WB = Western blotting; all antibodies are polyclonal, except Bcl-2 and Ki-67, which are monoclonal. 
Gene/Protein * 
Source of cDNA or riboprobe 
template 
Type of antibody  
Dilution 
in IHC 
Source 
GATA-4 m Ref. [222] 1:200 
 h For in situ III; for NB ref. [227] 
Rabbit-antimouse 
(human-reactive) 1:400 
Santa Cruz 
GATA-6 m - 1:200 
 h For in situ III; for NB ref. [36] 
Rabbit-antihuman 
(mouse-reactive) 1:50 
Santa Cruz 
FOG-2 m Ref. [12] (a 800 bp fragment) 1:500 
 h III 
Rabbit-antimouse  
(human-reactive) 1:100 
Santa Cruz 
AMH m - 1:200 
 h - 
Goat-antihuman 
(mouse-reactive) 1:100 
Santa Cruz 
SF-1 h - 1:800 Upstate 
   
Rabbit-antimouse  
(human-reactive)   
Bax h - Antirabbit 1:500 Pharmingen 
Bcl-2 h - Antimouse 1:25 DAKO 
Ki-67 h - Mouse-antihuman 1:150 DAKO 
Cyclophilin h Ref. [228] - - - 
GAPD h Ref. [229] - - - 
18S m Ambion - - - 
Actin m - Goat-antihuman (WB) Santa Cruz 
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10-20 min for antigen retrieval. Endogenous 
peroxidase activity was then blocked with 
3% hydrogen peroxide for 5 min, and 
nonspecific binding was blocked by using 
1.5% normal serum in 0.1% Tween-PBS for 
30-60 min. The primary antibodies (Table 4) 
were exposed for 1 h at 37°C, or overnight at 
4°C in 0.1% Tween-PBS. An avidin-biotin 
immunoperoxidase system (Vectastain Elite 
ABC Kit, Vector Laboratories, Burlingame, 
CA, USA) was utilized to visualize the 
bound antibody with diaminobenzidine 
(DAB, Sigma Chemicals, St. Louis, MO, 
USA) as a substrate for the peroxidase 
enzyme in the presence of 0.03% hydrogen 
peroxide. The sections were counterstained 
with hematoxylin. Nonimmune serum or 
PBS replaced the primary antibody to obtain 
a negative control for each antibody. Double 
immunohistochemistry for FOG-2 and MIS 
(I) was carried out so that the FOG-2 
protocol was finished with nickel-DAB 
(Vector Laboratories), followed by exposure 
of AMH antibody on the same slides, which 
was then visualized by DAB. Ki-67 analysis 
was carried out with a Dako TechMate 500 
automated staining machine. 
 
6 In situ DNA 3’-end labeling (II) 
 
Apoptosis in the ovarian samples was 
analyzed by employing an in situ DNA 3'-
end labeling kit (Oncor, Gaithesburg, MD, 
USA). Paraffin-embedded sections were 
deparaffinized and hydrated, and the cell 
membranes were permeabilized by 
incubating the sections with proteinase K 
(Boehringer Mannheim GmbH, Mannheim, 
Germany) in PBS for 15 min. Endogenous 
peroxidase activity was blocked with 5% 
hydrogen peroxide for 5 min. DNA 
fragmentation was identified by applying 
terminal transferase enzyme with 
digoxigenin-labeled nucleotides to the 
sections for 1 h under coverslips. Anti-
digoxigen antibody was used to recognize the 
digoxigen-labeled nucleotide chains attached 
to the 3'-ends of DNA in the samples. A 
color reaction was produced with DAB in the 
presence of 0.03% hydrogen peroxide, and 
the sections were counterstained with 
hematoxylin. 
 
7 Light microscopy and scoring of 
results (I-IV) 
 
In all cases, the tissue samples that were 
subjected to RNA in situ hybridization, 
immunohistochemistry, or in situ DNA 3'-
end labeling were evaluated with light 
microscopy; the RNA in situ sections under 
both bright and dark-field optics. In Study II, 
the results were scored into negative, 
moderately positive, positive, strongly 
positive, and very strongly positive classes. 
In Study IV, the immunohistochemically 
stained sections of a normal adult ovary 
(n=3) and of the tissue microarray were 
scored blinded to the clinical data and 
separately by two researchers, with a 
consensus reached in cases of disparate 
scoring. When heterogeneous staining was 
detected, the strongest and weakest stainings 
of the four tissue cores of individual tumors 
in the microarray were omitted from the 
analysis. Granulosa cells from normal 
ovaries were scored to establish the 
immunoreactivity of normal proliferating 
granulosa cells of primary to medium-sized 
antral follicles. Scoring classes were as 
follows: 1) For the nuclear antigens (GATA-
4, GATA-6, FOG-2, and SF-1) 
negative/weak for 0-20% positive nuclei, or 
up to 100% positive nuclei with very weak 
intensity; intermediate for 20-80% positive 
nuclei with moderate or strong intensity; high 
for >80% positive nuclei with moderate or 
strong intensity. 2) For the cytoplasmic 
antigen (AMH) negative for 0% positive 
cells; weak for 1-20% positive cells or <80% 
positive cells with weak intensity; 
intermediate for >20% positive cells with 
moderate intensity; high for >20% positive 
cells with strong intensity or >80% of 
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positive cells with moderate to strong 
intensity. 
 
8 Statistical analysis (I, III, IV) 
 
The results of transient transfection assays 
were analyzed by ANOVA, followed by 
Duncan’s multiple range test to reveal 
significant differences (I). In GL-cell 
experiments, the data were analyzed by 
Student's t-test to reveal significant 
differences between untreated and hormone-
stimulated cultures (III). In Study IV, the 
three or four categorical scoring results were 
combined into two to represent normal 
expression reflecting immunoreactivity in 
normal granulosa cells, and reduced 
expression compared with normal 
immunoreactivity. The resulting nominal 
variables were analyzed with contingency 
tabling (2x2) and chi-square or Fisher’s exact 
tests. In addition, a logistic regression model 
was employed for multivariate analysis, in 
which each of the clinical measures was the 
dependent variable. The analyses were 
carried out using Exstatics or Statview 5.0.1 
softwares for Macintosh®. P<0.05 was 
considered significant. 
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RESULTS AND DISCUSSION 
 
1 GATA-4 and FOG-2 in ovarian 
development (I, II) 
 
Mammalian gonadogenesis is a complex 
orchestration of events requiring cooperation 
between a number of genes and 
corresponding proteins. The Y chromosome 
is the primary determinant of the path taken, 
with the rest depending on hormones, 
paracrine factors, intracellular signal 
mediators, and transcription factors that 
activate genes in the nucleus of a given cell. 
Previous studies have shown that 
transcription factors GATA-4 and GATA-6 
are expressed in the fetal mouse ovary and 
testis [34-36]. These factors functionally 
synergize with other cell-specific 
transcription factors, SF-1 being an important 
example [7]. In preliminary studies, FOG-2, 
the closest cofactor of GATA-4, was also 
detected in fetal mouse gonads [12,13].  
Little was, however, known about the 
expression and role of GATA-4 and FOG-2 
in the earliest phases of ovarian development.  
 
1.1 Expression and role in bipotential 
mouse gonads 
 
We assessed the expression of GATA-4 and 
FOG-2 in the bipotential urogenital ridge (I). 
Mouse embryos were sacrificed, the sex 
verified, and the urogenital ridge identified 
from serial sections of paraffin-embedded 
tissue. In situ hybridization analysis revealed 
GATA-4 and FOG-2 mRNA to be readily 
expressed in the bipotential urogenital ridge 
of both sexes at E10.5 (Figure 2A-D in I). 
Immunohistochemistry verified the 
corresponding proteins in the somatic cells of 
the urogenital ridge, whereas the germ cells 
(identified by morphology) presumably 
remained negative (Fig 3A-B in I). At E12.5, 
when Sry expression was about to cease, the 
gonads hardly showed any signs of 
differentiation; GATA-4 and FOG-2 
expression was still evident in the somatic 
cells of both sexes. In addition to our 
findings in mice, GATA-4 expression has 
been detected the undifferentiated rat and 
porcine gonads [230,231], suggesting a role 
in the formation of the mammalian gonad 
from the urogenital ridge. Gata4-deficient 
mice die prior to gonadogenesis [19,20], and 
a different approach confirmed that GATA-
4:FOG-2 interaction is essential for 
gonadogenesis [74]. Accordingly, abrogation 
of their cooperation resulted in reduced Sry 
expression, absent Sox9 and AMH 
expression, and subsequent failure in early 
testicular differentiation; the phenotype of 
female transgenic mice has not been reported 
in detail [74]. In fact, Sry promoter seems to 
be a direct GATA-4 target, and forced 
expression of a dominant negative GATA-4 
protein in the urogenital ridge of male mice 
may impair testis development (R. S. Viger, 
pers. comm. 2004). Thus, GATA-4 
presumably assists the genes promoting testis 
differentiation of the bipotential gonad. 
 
1.2 GATA-4 and FOG-2 in somatic cells 
during fetal life 
 
Previous studies have depicted GATA-4 
expression as being downregulated in the 
fetal mouse ovary after the bipotential stage 
[35]. Our survey, however, revealed a 
somewhat different pattern; GATA-4 
expression as well as FOG-2 expression, 
remained at a high level in the somatic cells 
of the mouse ovary over the entire fetal 
period (Figures 1-3 in I). In the fetal testis, 
FOG-2 was only weakly detectable in E13.5 
and absent in E15.5 Sertoli cells (I, and 
[232]). Further, AMH expression was evident 
in the FOG-2-negative Sertoli cells (Figure 4 
in I). mRNA in situ and Northern analysis 
verified strong GATA-4 and FOG-2 
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expression in the fetal ovary, whereas in the 
fetal testis the FOG-2 levels were 
significantly lower than those postnatally 
(Figures 1 and 2 in I). With respect to the 
findings of Viger et al. [35], reasons such as 
lack of an antigen retrieval method in 
immunohistochemistry or analysis of a 
different mouse strain may underlie the 
contrasting results that they obtained on 
GATA-4 expression in fetal gonads. 
 
In addition to mouse tissues, GATA-4 and 
FOG-2 expressions were analyzed in the fetal 
human ovary (II). Northern and in situ 
analysis of GATA-4 revealed mRNA 
expression in week 18, 22, 24, 27, 35, and 39 
fetal ovaries (Figure 3 in II). Further, GATA-
4 protein was very strongly expressed in 
pregranulosa/stromal cells at weeks 13 and 
14 (Table 1 and Figure 2G-I in II), when 
primordial follicles were not yet evident. 
During weeks 16-33, GATA-4 protein 
expression was somewhat reduced in the 
follicular granulosa cells. Besides GATA-4 
expression in situ analysis indicated FOG-2 
mRNA expression in week 21 and 24 
ovaries, and by immunohistochemistry the 
FOG-2 protein was localized to somatic and 
occasional germ cells at weeks 14-39 
(Anttonen et al., unpublished data). The 
putative role of GATA-4 in protecting 
follicles from apoptosis, i.e. atresia [36,165] 
was also addressed in the fetal ovary (II). 
While the oocytes represented the majority of 
apoptotic cells, occasional somatic cells, 
pregranulosa or follicular, underwent 
apoptosis throughout gestation and 
correspondingly expressed the apoptosis-
promoting Bax (Table 1 and Figures 1 and 2 
in II). The high GATA-4 expression in 
somatic cells may be interpreted as indicating 
a survival role for GATA-4. 
 
In the fetal human ovary, the SF-1 expression 
profile differs significantly from that in the 
mouse, and, similarly to GATA-4, it is not 
dimorphic in the gonads (I, and [233,234]). 
Following sexual differentiation, SF-1 is 
widely expressed in ovarian somatic cells 
[233]. These findings imply that GATA-4, 
SF-1, and perhaps FOG-2 are pivotal in 
granulosa cell survival, from their 
differentiation in fetal life onwards. Although 
high GATA-4 expression in the fetal ovary 
has been consistently verified in four 
mammalian species (I, II, and [230,231]), the 
ultimate role of GATA-4 in fetal 
development of the mammalian ovary 
requires further analysis.  
 
1.3 FOG-2 as a putative AMH repressor 
in the fetal ovary 
 
In the fetal testis, AMH is activated as part of 
the testicular cascade, enabling adequate 
development of the male reproductive organs 
from the sex ducts. As discussed previously 
(Section 2.2 in Review of the Literature), 
AMH activation in the early mouse testis 
involves Sox9, SF-1, and GATA-4 
[41,58,62], and in the early mouse ovary 
these activators are either not expressed, e.g. 
Sox9, or downregulated, e.g. SF-1, beyond 
the indifferent stage (Figures 3 and 7). 
However, the situation is different with 
GATA-4 (I), indicating that the ovary must 
possess tools to hamper AMH activation by 
GATA-4 and SF-1 synergism in the 
bipotential gonad. Given the dimorphic 
expression of FOG-2 in fetal somatic cells, 
we addressed one possible mechanism by 
utilizing transient transfection assays with the 
AMH promoter construct and expression 
plasmids for GATA-4 and FOG-2 (I). We 
found that FOG-2 was able to downregulate 
the activation of the AMH promoter by 
GATA-4 in cultured granulosa cells (KK-1 
cell line) (Figure 5 in I), suggesting that 
FOG-2 could indeed have this kind of 
function in the fetal ovary (I). Corresponding 
results have also been obtained in primary rat 
Sertoli cell cultures [72], in which the 
activity of the AMH promoter was repressed 
by overexpression of FOG-2. Furthermore, a 
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truncated GATA-4, which works as 
dominant negative competitor for the 
endogenous GATA-4, was able to 
downregulate the AMH promoter activity. 
The results of Tremblay et al. [72] also 
indicate that without a need to bind the 
GATA site in the promoter, GATA-4 may 
promote AMH activation directly through the 
SF-1 protein.  
 
A mammalian female lacks the Y 
chromosomal Sry, which is necessary for 
testis development [37,41] and may act to 
facilitate testicular gene activation by 
epigenetic mechanisms [46]. The Sry 
promoter is directly activated by SF-1 and 
GATA-4, and both factors are expressed in 
the bipotential urogenital ridge of both sexes 
(Figure 7) (I, and [41]). Regulation of AMH 
involves the same factors as well as the Sry-
driven Sox9, which is key in activating the 
AMH promoter in the testis [62,66]. Sox9 
levels are negligible in the fetal ovary, and 
sustained expression of FOG-2 and DAX-1 
could provide additional tools for 
guaranteeing that AMH remains unexpressed 
(Figure 7). However, more robust analysis 
utilizing transgenic mice is required to 
consistently relate our findings on FOG-2 to 
gonadogenesis and ovarian development in 
vivo.
 
 
 
 
 
Figure 7. Expression and proposed 
function of GATA-4, FOG-2, SF-1, and 
DAX-1 in AMH regulation and sex 
differentiation in the mouse (see also 
Figures 2 and 3). Beyond the bipotential 
stage, expression of AMH activators 
GATA-4 and SF-1 is retained in the 
testis, whereas only GATA-4 is retained 
in the ovary. Expression of AMH 
repressors FOG-2 and DAX-1 is 
downregulated in the testis, but retained 
in the ovary to suppress AMH. 
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2 GATA-4, GATA-6, and FOG-2 in 
ovarian function (I, III, IV) 
 
Ovarian folliculogenesis is regulated by 
endocrine and paracrine mechanisms. The 
intracellular response of a given cell to 
hormonal stimulation employs secondary 
ligand-specific messengers that activate 
transcription factors to drive gene expression. 
Previous studies have shown expression of 
GATA transcription factors in mouse 
endocrine organs, i.e. in the adrenals, testis, 
and ovary [31,34-36]. Over the course of our 
studies, GATA-4 appears to have evolved as 
an effector in the gonadotropin cascade 
(Figure 5) [7]. Furthermore, GATA 
transcription factors and FSH share several 
endocrine target genes in the ovarian 
granulosa cells, including LHR, AMH, 
inhibin, and aromatase [7,34,64,235].Taken 
together, these findings prompted studies on 
the expression and function of GATA and 
FOG factors in the human ovary.  
 
2.1 Expression patterns during 
folliculogenesis  
 
Granulosa cells of primordial follicles, 
formed during fetal life in human, preserve 
the oocytes until their extinction at 
menopause; folliculogenesis is activated 
around puberty. We found no GATA-4 
expression in primordial follicles, but at the 
onset of growth (i.e. initial recruitment) and 
transformation into primary follicles via an 
intermediary stage, GATA-4 expression was 
initiated in granulosa cells (Figure 8 in next 
page and Figure 2 in III). With further 
development of the follicles, granulosa cells 
of preantral and antral follicles uniformly 
expressed GATA-4 protein. 
Immunoreactivity for GATA-4 was localized 
to cumulus and mural granulosa cells, theca 
cells, and stromal cells, whereas oocytes 
remained negative. In situ mRNA analysis 
confirmed the GATA-4 expression pattern 
(Figure 1A-B in III).  
Expression patterns for GATA-6 and FOG-2 
proteins somewhat resembled each other 
during human folliculogenesis (Figure 8). 
Granulosa cells of primary follicles had 
negligible or weak immunoreactivity, but in 
later follicular stages GATA-6 and FOG-2 
proteins were expressed in most follicular 
granulosa cells. FOG-2 was also expressed in 
fallopian tubes and occasional oocytes 
(unpublished observations). In situ analysis 
for GATA-6 mRNA (Figure 1C-D in III) 
revealed expression also in the luteal glands. 
In addition to the results on full ovarian 
tissue samples, mRNA expression for 
GATA-4, GATA-6, and FOG-2 was 
observed in freshly isolated human granulosa 
cells of preovulatory follicles from women 
undergoing IVF treatments (Figure 4 in III). 
Thus, both mRNA and protein of GATA-4, 
GATA-6, and FOG-2 were expressed in 
granulosa and theca cells of growing human 
follicles (III and IV). 
 
FOG-2 expression was also surveyed in the 
postnatal mouse ovary and was generally 
detected in parallel to GATA-4 expression, 
i.e. in granulosa cells from primary follicles 
onwards (I). However, a few granulosa cells 
in the primordial follicles readily expressed 
FOG-2 while GATA-4 was negative, but in 
antral follicles FOG-2 expression was more 
often downregulated while GATA-4 
expression was retained (Figure 6 in I). In 
addition, FOG-2 was coexpressed with 
GATA-6 in luteal glands and in the mucosa 
of fallopian tubes, which remained GATA-4 
negative (Figure 7 in I). The FOG-2 
expression pattern in mouse and human 
specimens suggests a broader role for FOG-2 
in the mammalian reproductive tract, than 
merely being a GATA cofactor. In support of 
this, recent evidence shows that FOG-2 may 
belong to a family of other transcriptional 
repressors [236].  
  
RESULTS AND DISCUSSION 
 
 42 
2.2 Gonadotropin regulation of GATA 
factors 
 
Gonadotropins have a fundamental impact on 
folliculogenesis; especially FSH is required 
for development from preantral to antral 
follicles [97,162]. FSH and forskolin (mimics 
FSH effects) were previously shown to be 
able to upregulate GATA-4 mRNA levels up 
to 1.7-fold in murine granulosa tumor cells 
(NT-1 cell line), which resemble normal 
granulosa cells [36]. In addition, treatment of 
premature three-week-old mice with 
gonadotropin from pregnant mare serum 
(PMSG) enhanced follicular expression of 
GATA-4 and GATA-6 transcripts [36]. To 
address this phenomenon in humans, we 
utilized cultures of isolated preovulatory 
human granulosa cells (III). These cells are 
derived from women undergoing 
hyperstimulation treatments to provide 
oocytes for IVF, they luteinize during in vitro 
cultures, and are thus called granulosa-luteal 
(GL) cells. Treatments with recombinant 
human FSH, hCG, or 8-Br-cAMP (a cell 
membrane permeable analog of cAMP) had 
no effect on steady-state levels of GATA-4 
and FOG-2 in GL cells (III). Instead, GATA-
6 mRNA levels were modestly but 
significantly upregulated by hCG (Figure 5 
Figure 8. Expression of 
GATA-4, GATA-6, and 
FOG-2 in human 
folliculogenesis. Primary 
follicles are presented in 
the left panels, and a 
small antral follicle in 
the right panels. Brown 
indicates positive 
immunohistochemical 
staining in nuclei for 
these antigens. Sections 
are counterstained with 
hematoxylin, resulting in 
blue nuclei. GATA-4 
expression is highly 
positive in follicles at 
both stages, whereas 
GATA-6 and FOG-2 
expression is somewhat 
weaker or negative at the 
primary stage but 
positive at the antral 
stage. The scale bar for 
both sets of panels 
represents 50 µm.  
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in III). In addition, 8-Br-cAMP upregulated 
GATA-6 mRNA levels within 2 h of 
stimulation of GL cells. These effects on 
GATA-6 rather than on GATA-4 may well 
reflect the luteinized phenotype of GL cells, 
given that only GATA-6 is expressed in 
luteal glands, both in the human and in the 
mouse ovary (I and III). 
 
Several lines of evidence indicate an 
essential role for GATA factors in the 
gonadotropin pathway. In addition to 
granulosa cells, postnatal testicular Sertoli 
and Leydig cells express GATA-4, and 
Leydig cells and adrenal cortical cells 
express GATA-6 [31,34,234,237]. In 
testicular Sertoli and Leydig tumor cells, 
mRNA levels for GATA-4 are modestly but 
significantly upregulated in vitro by hCG 
and/or FSH [34,36], and in human 
adrenocortical cells stimulation with (Bu)2-
cAMP (analog of 8-Br-cAMP) resulted in a 
3-fold increase in GATA-6 mRNA levels 
[238]. Furthermore, Tremblay et al. found 
that in primary Sertoli cells the GATA-4 
protein levels remained stable when 
stimulated by cAMP, and instead the serine 
261 of the GATA-4 protein was 
phosphorylated by PKA, resulting in 
enhanced transcription-driving activity of 
GATA-4 [7,108,109]. In the case of GL cells, 
GATA-4 may well be phosphorylated upon 
FSH, hCG, or cAMP stimulation, despite the 
lack of increase in GATA-4 mRNA (III).  
 
In women with an inactivating mutation in 
the FSHR, GATA-4 expression is negative in 
the large pool of primordial follicles [239]. 
However, granulosa cells of primary follicles 
in these patients readily express GATA-4 
(unpublished observations), suggesting that 
either FSH or FSHR is not required for the 
initial activation of GATA-4 expression, 
which instead may involve oocyte-derived 
factors. Of these, GDF9 is the most plausible 
candidate given its mitogenic activity and 
growth arrest of follicles in GDF9 deficiency 
[126-130]. From a clinical point of view, the 
phenotype of Gdf9-null mice closely reflects 
the changes in hypergonadotropic 
hypogonadism [113]. In FSHR-null mice 
with a corresponding phenotype, follicle 
growth is arrested at the preantral stage, 
resulting in decreased estradiol levels due to 
lack of antral follicles [100,102]. In addition, 
GATA-4 expression in these follicles is 
impaired in 10-day-old animals compared 
with age-matched wildtype animals [102]. 
Taken together, the temporal and spatial 
presence of GATA-4 and GATA-6 in the 
mammalian ovary (I-IV, and  [36,230,231]) 
provides granulosa and theca cells with an 
essential nuclear effector for the 
gonadotropins to drive cell-specific gene 
expression, including expression of receptors 
for themselves [235]. 
 
2.3 Activation of granulosa cell gene 
inhibin-α requires GATA 
 
Inhibin-α, essential in the ovarian function, is 
predominantly expressed in the granulosa 
cells of growing follicles [122]. Providing a 
major negative feedback mechanism from the 
gonads to the pituitary gonadotropin 
production, FSH activates inhibin expression 
in granulosa cells [122,133]. Along with 
characterizing GATA-4 expression in the 
mouse ovary and testis, inhibin-α was shown 
to be a direct target gene for GATA factors in 
the gonads [34,36]. Accordingly, GATA-4 
specifically binds its target sequence in the 
inhibin-α promoter (Ketola and Parviainen, 
unpublished data) and transactivates the 
promoter in synergy with SF-1, as analyzed 
by in vitro transient transactivation assays of 
granulosa and Leydig cell lines [34,73]. 
Further, when the GATA-binding sites in the 
inhibin-α promoter were mutated, GATA-4 
was unable to activate the promoter [34]. In 
addition, in GL cells, the treatments that 
upregulated GATA-6 mRNA levels were 
also able to upregulate inhibin-α mRNA 
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levels, indicating indirectly the need for 
GATA factors in this process (III). 
 
Our most recent analysis has revealed that, in 
addition to a key role in the FSH cascade, 
GATA-4 is involved in the oocyte-derived 
TGF-β signal to activate inhibin-α in 
granulosa cells (Anttonen et al., unpublished 
data). GATA-4 enables the activation of 
inhibin-α promoter by TGF-β,  as indicated 
by the lack of a TGF-β effect on the 
promoter when GATA-4 was not 
overexpressed in non-GATA/non-SF-1-
expressing COS cells (Figure 9A). In 
transient transfection assays of KK-1 
granulosa cells, which endogenously express 
GATA-4 and SF-1, TGF-β readily stimulated 
the inhibin-α promoter, whereas mutations in 
the GATA-binding sites in the promoter 
resulted in abrogation of the TGF-β effect 
(Figure 9B). Furthermore, similarly to FSH, 
TGF-β was able to upregulate GATA-4 
protein expression in KK-1 cells (Figure 9C). 
Taken together, the results suggest that 
GATA-4 serves as a link between endocrine 
and oocyte-derived paracrine activation of 
inhibin production and is essential for the 
granulosa cell function. With respect to the 
yet unknown mechanisms activating GATA-
4 expression in granulosa cells of primary 
follicles, of interest is the activation of GDF9 
expression in oocytes at the same stage [117-
119], and GDF9 utilizing the same signaling 
cascade as TGF-β in granulosa cells 
[134,240]. These findings provide evidence 
that initiation of GATA-4 expression in 
granulosa cells involves the oocyte-derived 
factors.  
 
2.4 GATA factors integrate essential 
signaling pathways in granulosa cells 
 
Several endocrine target genes for GATA 
transcription factors have been identified 
while this study was underway 
[34,64,73,235,241,242]. In granulosa cells, 
Figure 9. Role of GATA-4 and GATA motifs 
in activation of inhibin-α by TGF-β.  A) COS 
cells were transfected with inhibin-α 
promoter and GATA-4 expression plasmid, 
and stimulated with 0, 2, or 10 ng/ml TGF-β. 
TGF-β stimulates the promoter only in the 
presence of GATA-4. B) KK-1 granulosa 
cells were transfected with a wild-type (wt) 
inhibin-α promoter, as in A, or with a 
promoter possessing mutations in either or 
both of the GATA motifs (mut1, mut2, 
mut1&2), and stimulated with 0 or 10 ng/ml 
TGF-β. Mutations in the GATA-binding sites 
abrogate the activation of inhibin-α promoter 
by TGF-β. C) TGF-β upregulates GATA-4 
protein levels in KK-1 granulosa cells, as 
analyzed by Western blotting of nuclear 
protein extracts. Actin is a control for equal 
loading of samples.  
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Figure 10. Proposed function of GATA-4 in 
integrating endocrine, paracrine, and 
autocrine regulation of granulosa cells (see 
also Figures 5 and 6). FSH and TGF-β 
upregulate GATA-4 expression. GATA-4 is 
phosphorylated (P) by PKA and putatively 
by ERK. GATA-4 is also employed by the 
TGF-β pathway to facilitate 
autocrine/paracrine regulation by activin, 
TGF-β, or the oocyte-derived GDF9. p38 is 
activated by TGF-β and may also 
phosphorylate GATA-4. Note that the listed 
target genes are either activated or 
suppressed by these pathways. 
 
regulation of GATA targets LHR, AMH, 
inhibin, and aromatase involves cooperative 
action between FSH, TGF-β and MAPK 
pathways (simplified presentation in Figure 
10). Evidence for the role of GATA-4 in the 
FSH pathway is consistent, and our recent 
data also suggest a role for GATA-4 in 
mediating the TGF-β signal in granulosa 
cells (Figure 9). TGF-β is already known to 
employ GATA-4 in T helper cells and 
cardiac cells to transactivate interleukin 5 
and Nkx2.5 genes, respectively [243,244]. 
The direct involvement of GATA-4 in the 
MAPK cascades has been established in 
cardiac cells, in which the induction of 
transcriptional activity of GATA-4 is 
mediated by ERK and p38 MAPK, which 
phosphorylate serine 105 in the GATA-4 
protein [27-29]. The capability of these 
kinases to phosphorylate and activate GATA-
4 in gonadal cells remains to be studied. In 
granulosa cells, however, the insulin-like 
growth factor activated cascade that involves 
MAPK has been demonstrated to employ 
GATA-4 to activate transcription of StAR 
(steroidogenic acute regulatory protein), yet 
another endocrine GATA target gene [245]. 
In addition, the present analysis of 
transcription factor expression in normal 
human ovaries indicate roles for GATA-4 
and GATA-6 in granulosa cells (II-IV). 
GATA-4 and GATA-6 seem to orchestrate 
the endocrine, paracrine, and autocrine 
signals essential for ovarian function (Figure 
10).
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3 Granulosa cell proliferation and 
tumorigenesis (III, IV) 
 
Folliculogenesis involves a balance of 
granulosa cell proliferation and apoptosis. 
This balance is essential to avoid inadequate 
proliferation of ovarian somatic/stromal cells 
and development of sex cord stromal tumors, 
such as granulosa or theca cell tumors, and 
epithelial cancer. In view of the expression 
profiles and the proposed functions of 
GATA-4 and GATA-6 in the human ovary 
(Figures 8 and 10), we addressed their 
contribution to granulosa cell proliferation as 
reflected by granulosa cell tumors (GCTs).  
 
3.1 Expression profiles in granulosa cell 
tumors 
 
mRNA analysis revealed that GATA-4, 
GATA-6, and FOG-2 are expressed in GCTs 
as well as in thecomas (theca cell tumors) 
(Figure 3A-B in III). In our first GCT study 
(III), all tumors examined expressed GATA-
4 (n=15) and FOG-2 (n=12), and most also 
expressed GATA-6 (9/10). In addition, all 
thecomas expressed GATA-6 (n=4) and 
FOG-2 (n=7), and most also GATA-4 (8/9). 
In this analysis, differences in mRNA levels 
were obvious but not quantified. Confirming 
the mRNA analysis, GATA-4 protein was 
also expressed in these tumors (Figure 3C-D 
in III). The findings suggest that these factors 
are required for granulosa and theca cell 
differentiation of the given tumors, and 
prompted a further analysis to profile their 
expression in a larger number of tumors (IV). 
 
Primary GCT tissue samples of 80 patients 
were collected from the archives of the 
pathology unit and embedded in a tissue 
microarray that enables high throughput 
studies on protein expression in tissue 
samples (IV) [220]. In addition, we 
scrutinized the detailed clinical histories of 
all of the patients at Women’s Hospital. The 
protein expression profiles for GATA-4, 
GATA-6, SF-1, FOG-2, and AMH were 
analyzed by immunohistochemistry, and the 
immunoreactivity levels in tumors were 
scored based on comparisons with levels in 
normally proliferating granulosa cells of 
primary/preantral and small/medium-sized 
antral follicles (Figure 11 in next page and 
Figure 2 in IV). The detailed analysis 
revealed that the majority of GCTs express 
GATA-4, GATA-6, SF-1, and FOG-2 at 
levels comparable with those in the normal 
granulosa cells (Table 5). The high 
expression of GATA-4 resembles the 
expression level in normal granulosa cells, 
whereas for the rest of the factors the normal 
level is intermediate or high. The findings 
support the hypothesis that GATA-4, GATA-
6, SF-1, and FOG-2 play a role in granulosa 
cell tumors. Moreover, the variations in 
immunoreactivity levels, i.e. normal 
sustained vs. reduced (abnormal) expression 
levels, enabled further analysis regarding the 
clinical behavior of GCTs (clinical features 
of patients presented in Table 1 in IV). 
3.2 AMH as a suppressor of granulosa 
cell tumor growth 
 
In contrast to the other factors studied, AMH 
expression was more often reduced in GCTs, 
being weak in 40% and negative in 29% of 
the GCTs (Table 5 and Figure 11). Thus, 
69% of GCTs exhibited significantly reduced 
Table 5. Protein expression profiles in 
primary granulosa cell tumors. 
 
  Scoring result, total n=80  
Antigen 
Negative or 
weak 
intermediate high 
GATA-4 5 (6%) 40 (50%) 35 (44%) 
GATA-6 23 (29%) 46 (57%) 11 (14%) 
SF-1 13 (16%) 50 (63%) 17 (21%) 
FOG-2 21 (26%) 41 (51%) 18 (23%) 
AMH 55 (69%) 17 (21%)   8 (10%) 
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AMH expression, compared with expression 
levels in granulosa cells of growing follicles 
(IV, and [121]). Subsequent statistical 
analysis proved that these tumors, especially 
the AMH negative ones, are significantly 
larger in size (Figure 3A in IV). Considering 
the function of AMH in suppressing both the 
initial growth recruitment of follicular 
granulosa cells and the growth factor/FSH-
stimulated granulosa cell proliferation [138-
141], the reduced AMH expression in GCTs 
could well be one of the defects causing 
misregulated proliferation of granulosa cells 
leading to GCTs. Decreased AMH 
production by tumor cells could promote 
inadequate proliferation of the cells in the 
immediate neighborhood, given that GCTs 
are reported to express receptors for AMH 
[246]. The potential of AMH to act as a 
growth inhibitor of ovarian, breast, and 
prostate cancer cells is of great interest 
[58,247-249], and further analyses of the 
prevalence of AMH receptors in GCTs and 
the usefulness of AMH as a therapeutic agent 
for GCT are warranted. 
The reduced (i.e. negative/weak) GATA-6 
expression found in 29% of the GCTs was 
also associated with an increase in tumor size 
(Figure 3A in IV). GATA-6 expression was 
associated with AMH expression as well, 
suggesting that, instead of or in addition to 
GATA-4, GATA-6 contributes to the 
regulation of AMH in normal and malignant 
granulosa cells. Postnatal regulation of the 
AMH promoter has been addressed in Sertoli 
cells, where its activation was found to be 
dependent on FSH, SF-1, and GATA-4 
[62,72,144,145]. The proposed role of FOG-
2 as a downregulator of AMH in the fetal 
ovary (Figure 7) may not be so obvious in the 
postnatal ovary considering that FOG-2 and 
AMH expressions significantly overlap in 
preantral follicles in mouse (Figure 6 in I). 
Nevertheless, since AMH activation in 
granulosa cells involves the oocyte-derived 
factors [146], GATA-4 may contribute in a 
similar manner as in the case of inhibin-α 
(Figure 9). 
 
Figure 11. Examples of GATA-
4 and AMH expression in two 
granulosa cell tumors. 
Immunohistochemical staining 
of GATA-4 (left panels; 
nuclear stain) and AMH (right 
panels; cytoplasmic stain) in 
tumor samples embedded in a 
tissue microarray. Upper 
panels (from one tumor) show 
an example of expression 
resembling normal granulosa 
cells, and lower panels (from 
one tumor) show expression 
level that is reduced level. 
Sections are counterstained 
with hematoxylin; scale bar 
represents 50 µm. 
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3.3 GATA-4 expression is associated 
with aggressive tumor behavior 
 
Our results suggest that GATA-4 facilitates 
granulosa cell proliferation and aggressive 
behavior in a subgroup of GCTs. An 
aggressive GCT is characterized by advanced 
clinical stage, large size, recurrence, and 
death of the GCT. Firstly, GATA-4 
expression was initiated at the same time as 
granulosa cells started to proliferate 
(presented in Section 2.1). Secondly, 94% of 
the GCTs expressed GATA-4 at a 
intermediate or high level, and 44% at a high 
level resembling the level found in normal 
granulosa cells (Table 5, and Figures 8 and 
11). Thirdly, in the clinical survey, the high 
GATA-4 expression was significantly 
associated with clinical stage Ic or higher and 
with risk of recurrence (Figure 3B-C in IV). 
High GATA-4 expression was detected in 18 
of the 30 tumors of stage Ic, II, or III. One 
should note here, that in stage Ic ovarian 
cancer the disease is no longer limited to 
within the ovary, stage II cancer often has 
pelvic extension, and stage III cancer has 
microscopically confirmed peritoneal or 
lymph node metastasis. In addition to clinical 
stage, tumor size is suggested to be useful in 
evaluating prognosis of a GCT patient [177], 
but in our patient series both of these failed 
to correlate with risk of recurrence, as an 
indicator of prognosis. By contrast, the high 
sustained GATA-4 expression in the primary 
GCT was significantly associated with 
recurrence risk in all 80 patients as well as in 
the 50 patients followed up for at least 10 
years (Figure 3C in IV; characteristics of 
recurred tumors in Table 2 in IV). We were, 
however, unable to associate any of the 
parameters studied with overall survival 
because of the low number of deaths due to 
GCT in these patients, a feature characteristic 
of this tumor type. 
 
Adrenocortical carcinomas have similarities 
with GCTs in that their genesis seems to be 
gonadotropin-dependent. 
Hypergonadotropism is involved in inducing 
tumorigenesis in certain mice strains after 
gonadectomy as well as in the inhibin-α null 
mice [33,250]. Interestingly, GATA-4 is 
upregulated along with tumorigenesis in 
these mice, whereas normal adrenocortical 
cells express GATA-4 only during fetal 
development [31-33]. In contrast to fetal life, 
the proliferation rate is low in postnatal 
adrenals, suggesting that the appearance of 
GATA-4 has an effect on adrenocortical 
proliferation. In addition, human adrenal 
carcinomas express GATA-4 [31,251]. Given 
also the common embryonic origin of 
adrenocortical cells and ovarian granulosa 
cells, i.e. the urogenital ridge, GATA-4 may 
serve as an essential element in proliferation 
of adrenal and ovarian cells. With respect to 
clinical practice, additional analyses are, 
however, required to assess whether GATA-
4 has prognostic value in the human GCTs.  
 
3.4 Granulosa cell tumor pathogenesis 
may involve GATA-4 
 
A proposal for the factors having an impact 
on granulosa cell tumorigenesis and tumor 
growth is presented in Figure 12 (evolved 
from Figures 6 and 10). Cyclin D2 is of 
special interest considering its role in 
granulosa cell proliferation and 
tumorigenesis [98,153,154,203]. The cyclin 
D2 promoter interestingly contains consensus 
GATA-binding site(s) [156,157], and 
although direct promoter analysis remains to 
be carried out, GATA-4 is able to upregulate 
cyclin D2 expression in pulmonary cell lines 
in stimulations that employ the ERK pathway 
[158]. In addition to supporting proliferation 
putatively through cyclin D2 activation, 
GATA-4 may protect the granulosa cells 
from undergoing apoptosis (II) by activating 
anti-apoptotic genes such as Bcl-X [36,165]. 
Taken together, the prominent expression of 
GATA-4 in GCTs may serve as a link for 
FSH and ERK signaling, both active in 
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GCTs, to promote the granulosa cell 
proliferation leading to malignancy. One 
possibility is that GATA-4 is activated by an 
as yet unknown mutation in the GATA4 gene. 
.
 
 
 
 
 
 
Figure 12. Simplified illustration of granulosa cell tumor molecular pathogenesis, 
in light of the results presented (see Figures 6 and 10 for comparison). Symbol ↑  
represents upregulation or active state in GCTs and symbol ↓  represents 
downregulation in GCTs. GATA-4 may enhance the tumorigenic actions of FSH 
and ERK, putatively by activating cyclin D2. GATA-6 and SF-1 may have an 
impact on aromatase and AMH expression. Lastly, the reduced AMH expression 
may impair the necessary autocrine suppression of granulosa cell proliferation. The 
impact of inhibin-α on human tumorigenesis remains unclear. 
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CONCLUSIONS AND FUTURE PROSPECTS 
 
Unraveling expression profiles of 
transcriptional regulators during development 
and tumorigenesis in the mammalian ovary 
provides the physiological context to address 
functional aspects. This information may 
ultimately help to improve diagnostic and 
treatment strategies for human disease. In 
addressing the aims of this series of studies, 
new questions and goals emerged to be 
addressed in future research. The main 
conclusions are as follows: 
 
1. Transcription factor GATA-4 is readily 
expressed in the coelomic epithelium of the 
mouse urogenital ridge, derived from the 
mesendodermal layer. Expression of GATA-
4 as well as cofactor FOG-2 occurs in the 
ovarian somatic cells throughout fetal and 
postnatal life in both mice and humans, 
indicating a role for these two factors in 
sustaining differentiated cell lineages in the 
ovary. During gonadal differentiation, FOG-
2 may support ovarian determination by 
inhibiting the AMH expression that 
determines the testis formation. 
 
2. Upon activation of folliculogenesis, 
GATA-4 expression is activated in the 
granulosa cells of primary follicles in the 
human ovary, and continues in these cells 
until follicular atresia or luteinization of the 
ovulated follicles, suggesting a role for 
GATA-4 in supporting granulosa cell 
proliferation. GATA-4 is necessary for 
inhibin-α expression in granulosa cells, 
whereas GATA-6 is involved in 
steroidogenic function of the granulosa and 
luteal cells. In general, the GATA 
transcription factors may prove to be 
essential in orchestrating the regulation of 
granulosa cell functions by endocrine and 
paracrine effectors.  
 
3. Misregulated granulosa cell proliferation 
may lead to malignant tumors. Most of the 
resulting granulosa cell tumors express 
GATA-4, supporting the role of GATA-4 in 
granulosa cell differentiation and 
proliferation. Furthermore, GATA-4 
expression remains at a high level and 
comparable with that in normal granulosa 
cells, especially in the more aggressive 
granulosa cell tumors that present in 
advanced clinical stage and recur during 
follow-up. By contrast, AMH, which is 
expressed in healthy granulosa cells, is 
usually downregulated in granulosa cell 
tumors. This may improve the growth 
potential of the tumors, given that AMH is a 
known growth inhibitor in cancer cells.  
 
Open questions and putative means to 
address these in future research include: 
 
1. Would abrogation of GATA-4 function 
in the early gonad abrogate ovarian 
development and differentiation? The most 
probable answer is yes; to prove this requires 
the development of an ovarian somatic cell-
specific Gata4-null mutation in mice. In fact, 
a testicular Sertoli cell-specific model has 
already been developed, but the results are as 
yet unreported (R. S. Viger, pers. comm. 
2004). With respect to human disorders in 
reproductive tract development, mutation of 
GATA4 could be involved in a subset of the 
syndromes. 
 
2. Is FOG-2 an anti-testis or ovarian-
determining factor? This can only be 
speculated about prior to development of a 
mouse model in which FOG-2 is ectopically 
expressed in the fetal testis. Mutation 
analysis in well-characterized human 
reproductive tract development disorders 
could also help to answer this question. 
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3. Is GATA-4 essential for healthy ovarian 
function? Based on our findings and the 
results of other studies, several lines of 
evidence suggest that GATA-4 is mandatory 
for ovarian function. A mouse model in 
which Gata4 is abrogated in postnatal 
granulosa cells would confirm this. An 
alternative approach would be to 
downregulate GATA-4 expression in 
cultured ovaries by, for example, adenoviral 
means.  
 
4. Is the high GATA-4 expression in 
granulosa cell tumors caused by activating 
mutations in the gene? If the answer by 
sequencing GATA4 in tumor DNA turned out 
to be yes, GATA-4 would be shown to be 
one of the as yet unknown links in the 
overactive FSH cascade during 
tumorigenesis. 
 
5. Are receptors for AMH prominently 
expressed in granulosa cell tumors? If yes, 
could AMH act as a therapeutic agent for this 
cancer? The first question could be answered 
by employing the recently developed AMH 
receptor II recognizing antibody with the 
granulosa cell tumor tissue microarray. To 
answer the second question, a pilot 
experiment with an in vitro culture of 
primary granulosa cell tumors and treatment 
with recombinant AMH would be useful. 
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